Litigation sought reimbursements for violations of state law in prescribing practices, charges to Medicaid program
HOUSTON--(BUSINESS WIRE)--Building on decades of holding pharmaceutical companies responsible for dangerous products and unlawful business practices, The Lanier Law Firm played a pivotal role supporting Texas Attorney General Ken Paxton in securing a $45 million settlement with Gilead Sciences, Inc. Announced on Oct. 22, the settlement resolves claims that the company offered illegal incentives to medical providers to prescribe its drugs over competitors’ medications.
In many cases, these prescriptions resulted in millions of dollars in claims submitted to Texas Medicaid in violation of the Texas Health Care Program Fraud Prevention Act. As outlined in the lawsuit, Gilead allegedly offered other incentives such as “free nurses” and reimbursement support services to further influence medical providers to prescribe the company’s products.
In the litigation initially filed in 2023, the firm’s Mark Lanier, Zeke DeRose, Jonathan Wilkerson and Alex Brown represented Health Choice Advocates, whose mission is to investigate and bring Medicaid fraud litigation against major pharmaceutical companies. Attorneys with the firm of McKool Smith PC served as co-counsel for the non-profit company.
“As we’ve seen in many other cases, Big Pharma is often motivated by corporate profits rather than what is best and safest for patients, and what is in compliance with the law,” says Mr. Lanier. “We are proud to stand with the State of Texas in exposing this kickback scheme and prevent further abuse of taxpayer funds and the Medicaid program.”
The firm is also supporting ongoing and separate litigation brought by the Attorney General against Bristol-Myers Squibb Co., Novartis and Eli Lilly and Company for similar claims of unlawful prescribing practices and fraud.
About the Lanier Law Firm
For more than 30 years, the men and women at The Lanier Law Firm have worked tirelessly, throughout the United States, to find unique and effective solutions for their clients. More than 60 skilled attorneys practice law in a broad array of areas, including business litigation, pharmaceutical litigation, asbestos exposure, oil and gas litigation, personal injury as well as defective and dangerous products, among others. Named an Elite Trial Law Firm by The National Law Journal, The Lanier Law Firm has offices in Houston, New York, Fort Worth and Los Angeles. To learn more, visit http://www.lanierlawfirm.com.
-- Clinical Program Adds a Potentially Differentiated Oral Peptide IL-23 Receptor Inhibitor to Gilead’s Inflammation Portfolio --
-- HCXT-2001 Has Potential as a Monotherapy or in Combination with Other Gilead Programs to Address Unmet Needs in Immune-Mediated Inflammatory Diseases --
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar Therapeutics Limited, a privately held, clinical-stage biotechnology company.
“HCXT-2001 adds a potentially differentiated oral approach to our growing inflammation pipeline, reflecting our commitment to addressing significant unmet patient needs,” said Dietmar Berger, MD, PhD, Chief Medical Officer of Gilead.
Share Key Highlights
HCXT-2001 is an investigational, clinical-stage, oral, macrocyclic peptide inhibitor of IL-23R with an extended half-life, offering a potentially differentiated approach to oral IL-23 pathway inhibition. IL-23R is a clinically validated target in immune-mediated inflammatory diseases, including Inflammatory Bowel Diseases (IBD), with potential applications in psoriasis. The transaction provides Gilead with worldwide rights to the IL-23R inhibitor program, including HCXT-2001, and further strengthens Gilead’s growing inflammation and immunology portfolio, where the company is building depth and optionality in selected immune-mediated diseases through multiple complementary mechanisms and modalities. “HCXT-2001 adds a potentially differentiated oral approach to our growing inflammation pipeline, reflecting our commitment to addressing significant unmet patient needs,” said Dietmar Berger, MD, PhD, Chief Medical Officer of Gilead. “We see potential for HCXT-2001 alone or in combination, including with emvistegrast, as a daily oral treatment for people living with IBD.”
“We are excited for Gilead to take HCXT-2001 forward and believe their scientific expertise and global development capabilities can help realize the full potential of this novel oral IL-23R inhibitor,” said Haibing Guo, Founder and CEO of PepStar. “This transaction marks a major milestone for our company and underscores the strength of our proprietary oral peptide platform. I feel incredibly proud of what our team has accomplished in just three years and excited about what lies ahead as we continue bringing innovative medicines to patients around the world.”
Transaction Details
Under the terms of the agreement, Gilead will acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar for $1.275 billion in upfront cash consideration, subject to customary adjustments, which is payable at closing. Closing of the transaction is subject to certain customary conditions. The transaction is expected to close in the fourth quarter of 2026.
This transaction is expected to reduce Gilead's GAAP and non-GAAP EPS by approximately $0.79 to $0.83 in the fourth quarter of 2026.
Lazard is acting as the exclusive financial advisor for Gilead. Centerview Partners LLC is acting as the exclusive financial advisor for PepStar. Covington & Burling LLP and Mayer Brown LLP are serving as legal counsel to Gilead. Sidley Austin LLP is representing PepStar and Wilson Sonsini Goodrich & Rosati LLP are serving as patent counsel to PepStar.
Advancing Gilead's Commitment to Inflammation
Gilead is committed to advancing innovative treatments with the potential to transform care for people living with chronic inflammatory conditions.
The company is building a disciplined, differentiated inflammation portfolio focused on significant unmet needs across immune-mediated diseases. By combining immunology expertise, precision oral medicines and a deep internal pipeline spanning complementary scientific approaches, Gilead has the optionality to advance both monotherapies and future combinations that address underlying drivers of disease and improve outcomes that matter most to patients.
Our areas of focus include inflammatory bowel disease, type 2 inflammatory diseases, lupus and B cell-mediated autoimmune diseases.
About HCXT-2001
HCXT-2001 is an investigational oral macrocyclic peptide inhibitor of IL-23R with an extended half-life currently in Phase 1 clinical trials, originally developed by PepStar Therapeutics Limited. Its safety and efficacy have not been established, and it has not been approved by any regulatory authority.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.
Gilead Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the ability of Gilead and PepStar to complete the acquisition transaction in a timely manner or at all; the possibility that various closing conditions for the acquisition may not be satisfied or waived, including the possibility that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the acquisition; uncertainties relating to the timing or outcome of any filings and approvals relating to the acquisition; difficulties or unanticipated expenses in connection with integrating HCXT-2001 and related acquired assets; the effects of the acquisition on relationships with business partners or governmental entities; the risk that Gilead may not realize the expected benefits of this acquisition; the ability of Gilead to advance the acquired pipeline assets, including HCXT-2001, and successfully commercialize such assets following the acquisition; Gilead’s ability to initiate, progress or complete clinical trials or studies within currently contemplated timelines or at all, and the possibility of unfavorable results from ongoing or additional clinical trials or studies, including those involving HCXT-2001 and/or emvistegrast; uncertainties relating to regulatory applications and related filing and approval timelines, including potential applications for programs and/or indications currently or prospectively under evaluation, and the risk that any regulatory approvals, if granted, may be subject to significant limitations on use or subject to withdrawal or other adverse actions by the applicable regulatory authority; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and other factors are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements.
Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.
For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).
Gilead Sciences (GILD - Free Report) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
The earnings report, which is expected to be released on October 29, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus EstimateThis HIV and hepatitis C drugmaker is expected to post quarterly earnings of $2.16 per share in its upcoming report, which represents a year-over-year change of -12.6%.
Revenues are expected to be $7.81 billion, up 0.6% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 0.29% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Gilead?For Gilead, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +2.24%.
On the other hand, the stock currently carries a Zacks Rank of #2.
So, this combination indicates that Gilead will most likely beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Gilead would post a loss of$7.07 per share when it actually produced a loss of -$6.75, delivering a surprise of +4.53%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Gilead appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present new clinical and real-world evidence across primary biliary cholangitis (PBC) and chronic hepatitis delta virus (HDV) infection at The Liver Meeting® 2026, hosted by the American Association for the Study of Liver Diseases (AASLD), November 5-9 in Denver, Colorado. The data will examine durability of response, patient-relevant symptoms, and opportunities to better understand long-term disease management acro.
Gilead Sciences (GILD - Free Report) closed at $153.57 in the latest trading session, marking a -1.88% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 0.58% for the day. At the same time, the Dow added 0.69%, and the tech-heavy Nasdaq gained 1.05%.
Prior to today's trading, shares of the HIV and hepatitis C drugmaker had gained 2.52% lagged the Medical sector's gain of 3.5% and outpaced the S&P 500's gain of 0.97%.
The investment community will be closely monitoring the performance of Gilead Sciences in its forthcoming earnings report. The company is scheduled to release its earnings on October 29, 2026. The company is forecasted to report an EPS of $2.16, showcasing a 12.55% downward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $7.81 billion, up 0.59% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$0.47 per share and revenue of $30.76 billion, indicating changes of -105.77% and +4.47%, respectively, compared to the previous year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Gilead Sciences. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.14% higher. Gilead Sciences presently features a Zacks Rank of #2 (Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 101, which puts it in the top 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
CWA Asset Management Group LLC increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 24.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 78,639 shares of the biopharmaceutical company’s stock after acquiring an additional 15,240 shares during the period. CWA Asset Management Group LLC’s holdings in Gilead Sciences were worth $11,721,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Warwick Investment Management Inc. bought a new stake in shares of Gilead Sciences in the third quarter valued at about $213,000. Retirement Planning Group LLC grew its holdings in shares of Gilead Sciences by 26.6% during the third quarter. Retirement Planning Group LLC now owns 2,713 shares of the biopharmaceutical company’s stock worth $404,000 after buying an additional 570 shares in the last quarter. Tanager Wealth Management LLP bought a new position in shares of Gilead Sciences during the third quarter worth about $217,000. Trellis Wealth Advisors LLC bought a new position in shares of Gilead Sciences during the third quarter worth about $33,000. Finally, Clark Financial Services Group Inc. BD raised its position in Gilead Sciences by 14.0% in the 3rd quarter. Clark Financial Services Group Inc. BD now owns 4,732 shares of the biopharmaceutical company’s stock valued at $705,000 after buying an additional 581 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.
Gilead Sciences Trading Down 2.0% Shares of GILD stock opened at $153.07 on Tuesday. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. The company has a fifty day moving average price of $147.59 and a two-hundred day moving average price of $137.39. Gilead Sciences, Inc. has a one year low of $114.02 and a one year high of $160.51.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last announced its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. The company had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The company’s quarterly revenue was up 10.6% on a year-over-year basis. During the same quarter last year, the firm posted $2.01 EPS. On average, research analysts anticipate that Gilead Sciences, Inc. will post -0.47 earnings per share for the current year. Gilead Sciences Announces Dividend The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th were issued a dividend of $0.82 per share. The ex-dividend date was Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.1%. Gilead Sciences’s dividend payout ratio (DPR) is presently -122.85%.
Analyst Upgrades and Downgrades Several equities research analysts have commented on GILD shares. Weiss Ratings upgraded Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, September 14th. Royal Bank Of Canada upped their price target on Gilead Sciences from $123.00 to $126.00 and gave the stock a “sector perform” rating in a research report on Thursday, October 8th. Morgan Stanley decreased their price target on shares of Gilead Sciences from $165.00 to $163.00 and set an “overweight” rating for the company in a research note on Wednesday, October 7th. Truist Financial lifted their price objective on shares of Gilead Sciences from $150.00 to $158.00 and gave the company a “buy” rating in a report on Wednesday, October 7th. Finally, Zacks Research lowered shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 29th. Twenty-three analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $159.33.
Read Our Latest Analysis on Gilead Sciences
Insider Buying and Selling at Gilead Sciences In other Gilead Sciences news, Director Anthony Welters sold 18,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total value of $2,675,160.00. Following the sale, the director owned 12,894 shares in the company, valued at $1,916,306.28. This represents a 58.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $137.64, for a total value of $3,853,920.00. Following the completion of the sale, the insider directly owned 118,234 shares of the company’s stock, valued at approximately $16,273,727.76. The trade was a 19.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 111,000 shares of company stock valued at $15,877,860 in the last three months. Corporate insiders own 0.30% of the company’s stock.
Gilead Sciences News Summary Here are the key news stories impacting Gilead Sciences this week:
Positive Sentiment: Gilead reported positive Phase 2 SWIFT trial results for emvistegrast, an oral treatment for active ulcerative colitis. The drug met the trial’s primary goal, strengthening Gilead’s inflammatory bowel disease pipeline and providing potential long-term diversification beyond its HIV franchise. Gilead’s pill succeeds in mid-stage bowel disease trial Positive Sentiment: Analysts at Zacks upgraded GILD to Rank #2, or “Buy,” citing improving earnings prospects. The upgrade could support near-term investor interest, although it is a ratings-based catalyst rather than a change to the company’s fundamentals. All You Need to Know About Gilead Rating Upgrade to Buy Positive Sentiment: Gilead said it will present 28 studies at IDWeek 2026 covering HIV treatment, prevention and emerging antiviral programs. The presentations could provide additional visibility into future products and support expectations for continued innovation. Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026 Neutral Sentiment: Reports highlighted Gilead’s recent FDA approvals and label expansions, while ETF activity showed that 43 funds added the stock. These developments may improve sentiment, but they do not necessarily create immediate revenue or earnings changes. Negative Sentiment: Investors remain focused on whether acquisitions of Arcellx and Tubulis will enhance profits or dilute the dependable returns generated by Gilead’s HIV portfolio and dividend. This integration and capital-allocation uncertainty may have limited the market’s reaction to the ulcerative-colitis trial success. What Has Changed About Owning Gilead Stock? Negative Sentiment: Two insiders, Andrew Dickinson and Johanna Mercier, each reportedly sold 3,000 shares. The transactions are modest relative to Gilead’s market capitalization but can add a slightly cautious signal. Gilead Sciences Profile (Free Report)
Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.
Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.
Further Reading Five stocks we like better than Gilead Sciences Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
Investors might want to bet on Gilead Sciences (GILD - Free Report) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.
The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.
Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements.
Therefore, the Zacks rating upgrade for Gilead basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.
Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.
For Gilead, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.
Harnessing the Power of Earnings Estimate RevisionsAs empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .
Earnings Estimate Revisions for GileadFor the fiscal year ending December 2026, this HIV and hepatitis C drugmaker is expected to earn -$0.47 per share, which is unchanged compared with the year-ago reported number.
Analysts have been steadily raising their estimates for Gilead. Over the past three months, the Zacks Consensus Estimate for the company has increased 39.1%.
Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
You can learn more about the Zacks Rank here >>>
The upgrade of Gilead to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
Gilead Sciences (GILD.O) said on Monday its experimental once-daily pill reduced symptoms of a chronic bowel illness in more patients than placebo in a mid-stage trial.
The drug, emvistegrast, was being tested in adults with moderate to severe ulcerative colitis, a chronic condition that causes inflammation and ulcers in the digestive tract
The pill is designed to block the α4β7 integrin pathway, a target already validated in inflammatory bowel disease
After 12 weeks, 66% of patients taking a 200 mg dose of the drug saw their disease symptoms improve, compared to 37% on placebo, meeting the trial's main goal
Also, 31% of patients receiving the treatment achieved clinical remission, compared to 8% of those in the placebo group
BMO Capital Markets analysts said they view the data as "an incremental positive for Gilead's inflammatory strategy that establishes emvistegrast as a credible oral α4β7 option"
The drug was generally well tolerated, with overall side-effect rates comparable between the treatment and placebo groups, and no serious side effects were linked to the study medication
Gilead said it plans to initiate a late-stage monotherapy study of the pill in 2027
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its HIV and antiviral research and development programs at IDWeek 2026, taking place October 21-24 in Washington, D.C. The 28 presentations, including two oral presentations, will feature research in HIV treatment, HIV prevention and new insights into broader experiences of people living with HIV, as well as emerging antiviral programs. “We remain committed to advancing options for people a.
Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) CFO Andrew Dickinson sold 3,000 shares of the business’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total transaction of $468,660.00. Following the transaction, the chief financial officer owned 161,096 shares of the company’s stock, valued at $25,166,417.12. This represents a 1.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Gilead Sciences Price Performance NASDAQ:GILD opened at $156.19 on Monday. Gilead Sciences, Inc. has a one year low of $114.02 and a one year high of $160.51. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The firm has a market cap of $193.67 billion, a price-to-earnings ratio of -58.50 and a beta of 0.31. The firm’s fifty day moving average is $147.19 and its two-hundred day moving average is $137.29.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping the consensus estimate of ($7.25) by $0.50. The company had revenue of $7.80 billion for the quarter, compared to the consensus estimate of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The firm’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same period last year, the firm earned $2.01 EPS. Research analysts expect that Gilead Sciences, Inc. will post -0.47 EPS for the current year.
Gilead Sciences Dividend Announcement The business also recently announced a quarterly dividend, which was paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th were paid a $0.82 dividend. The ex-dividend date was Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.1%. Gilead Sciences’s dividend payout ratio is presently -122.85%. Institutional Investors Weigh In On Gilead Sciences Several hedge funds have recently modified their holdings of the company. Onyx Bridge Wealth Group LLC increased its position in shares of Gilead Sciences by 2.2% in the third quarter. Onyx Bridge Wealth Group LLC now owns 5,039 shares of the biopharmaceutical company’s stock valued at $751,000 after buying an additional 108 shares in the last quarter. IFP Advisors Inc raised its stake in shares of Gilead Sciences by 33.4% during the 3rd quarter. IFP Advisors Inc now owns 11,135 shares of the biopharmaceutical company’s stock worth $1,660,000 after buying an additional 2,788 shares during the period. Founders Grove Wealth Partners LLC lifted its position in shares of Gilead Sciences by 3.9% during the 3rd quarter. Founders Grove Wealth Partners LLC now owns 2,437 shares of the biopharmaceutical company’s stock valued at $363,000 after buying an additional 91 shares in the last quarter. Frank Rimerman Advisors LLC lifted its position in shares of Gilead Sciences by 1.2% during the 3rd quarter. Frank Rimerman Advisors LLC now owns 35,698 shares of the biopharmaceutical company’s stock valued at $5,321,000 after buying an additional 412 shares in the last quarter. Finally, Encompass More Asset Management lifted its position in shares of Gilead Sciences by 4.2% during the 3rd quarter. Encompass More Asset Management now owns 3,057 shares of the biopharmaceutical company’s stock valued at $456,000 after buying an additional 122 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes Several analysts recently commented on GILD shares. Weiss Ratings raised Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, September 14th. HSBC boosted their price target on Gilead Sciences from $155.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Bank of America restated a “buy” rating and issued a $164.00 price objective on shares of Gilead Sciences in a research report on Monday, October 12th. Barclays lowered their price objective on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 29th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 price objective on shares of Gilead Sciences in a research note on Thursday, October 8th. Twenty-three analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $159.33.
View Our Latest Stock Analysis on GILD
Key Stories Impacting Gilead Sciences Here are the key news stories impacting Gilead Sciences this week:
Positive Sentiment: Vir oncology collaboration expands Gilead’s pipeline. Gilead and Vir Biotechnology agreed to develop three novel cancer therapies, including next-generation T-cell engagers. The deal could provide Vir with up to approximately $1.74 billion in additional milestone payments, giving Gilead access to potential long-term oncology growth while diversifying its pipeline. Gilead and Vir forge $1.9bn pact to develop next-gen T-cell engagers Positive Sentiment: Investors are rotating toward defensive healthcare stocks. As investors reduce exposure to technology and chip stocks, major pharmaceutical companies—including Gilead—have traded near record highs. This rotation may be supporting demand for GILD because of the sector’s defensive characteristics and potential earnings support. Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets Neutral Sentiment: Recent momentum has increased investor attention. GILD gained 2.57% in the prior session and closed at $157.48, while shares remain close to their 52-week high. Market commentary notes heightened investor interest, although analysts have expressed mixed views on the company’s prospects. Gilead Sciences rises higher than market: Key facts Negative Sentiment: Two senior executives reported planned stock sales. CFO Andrew Dickinson and insider Johanna Mercier each sold 3,000 shares at an average price of $156.22. Both transactions were executed under pre-arranged Rule 10b5-1 plans, limiting their significance as a bearish signal; each executive continues to hold a substantial position. Gilead CFO Form 4 filing (Get Free Report)
Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.
Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.
Recommended Stories Five stocks we like better than Gilead Sciences These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington Meta Claims Frontier-Class AI Status With New Muse Wonder Models Berkshire Just Backed This Little-Known Stock—Should You Chase It? Broadcom’s CEO Sees Years of AI Demand But Warns of a Bigger Threat to the Boom
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
Gilead Sciences, Inc. (NASDAQ: GILD - Get Free Report) insider Johanna Mercier sold 3,000 shares of the firm's stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total transaction of $468,660.00. Following the transaction, the insider directly owned 113,684 shares of the company's
Gilead Sciences (GILD -0.75%), a biotech leader, has outperformed broader equities this year. The company's financial results have been fairly strong, contributing to its year-to-date performance. However, another factor behind Gilead Sciences' run is its important regulatory progress, which has improved its lineup of approved drugs. That's all well and good, but after climbing by almost 30% this year, are Gilead's shares still attractive?
Recent approvals could move the needle Over the past few years, Gilead Sciences has experienced declining sales from its coronavirus medicine, Veklury. The company's financial results have sometimes been mixed as a result, but things are trending up for the biotech giant. In the second quarter, Gilead Sciences' revenue came in at $7.8 billion, up 10% year over year. Product sales excluding Veklury also grew by 10% compared to the year-ago period. The company reported a non-GAAP loss per share of $6.75, compared to earnings per share of $2.01 in the year-ago period. The decline was mostly due to acquisition-related expenses.
Image source: Getty Images.
Gilead Sciences' core HIV portfolio was the primary driver of this performance. HIV product sales came in at $5.7 billion, up 12% year over year. The good news is that recent approvals (and label expansions) will help strengthen the company's HIV lineup and diversify its portfolio. In late August, Gilead Sciences announced that the U.S. Food and Drug Administration (FDA) had approved Bixlenvo, an HIV regimen. Bixlenvo is a daily oral tablet that combines two existing HIV medicines.
It helps simplify treatment for certain patients who were taking more than one pill per day. According to some estimates, that represents 5% of HIV patients in the U.S. That's in the neighborhood of 58,000 people. So, this market isn't huge. But the approval of Bixlenvo helps solidify Gilead Sciences' leadership position in the HIV market. Moving beyond HIV, Gilead Sciences received a label expansion for Trodelvy, a cancer medicine, in June. Trodelvy can now be used as a first-line treatment in metastatic triple-negative breast cancer.
The medicine was already indicated for previously treated breast cancer, but the first-line indication tends to be the most lucrative. That's because drugs approved as second- or third-line treatments are eligible for only a fraction of the patient pool, whereas being indicated as a first-line treatment means eligibility for all newly diagnosed patients. That's why the recent Trodelvy label expansion in one of the deadliest cancers in the world could be particularly important.
$156.19-$1.18 (-0.75%)
NASDAQ · As of 4:00 PM ET 10/16/26
Lastly, in May, Gilead Sciences earned approval for Hepcludex, a medication for chronic hepatitis delta virus (HDV) infection. It will be a nice addition to the company's liver disease portfolio, which is performing fairly well. Second-quarter liver disease sales came in at $877 million, up 10% year over year. Management expects Hepcludex to be a modest growth contributor in this segment.
A reliable dividend stock Gilead Sciences' brand-new approvals -- and the Trodelvy label expansion -- should help the company's revenue and earnings move in the right direction over the medium term as the impact of Veklury on its financial results fades. Of course, the biotech giant can still count on several of its flagship products. None is more important than Biktarvy, an HIV medicine. Biktarvy is the leading HIV treatment in the U.S. Descovy for PrEP is another important growth driver.
Gilead Sciences should also make significant clinical and regulatory progress over the next few years, especially in HIV and oncology. So, the company's financial results should remain strong in the medium term. Here's another good reason to consider Gilead Sciences: It is a solid dividend stock. The company boasts a forward yield of 2.2%, compared with the S&P 500's average of 1.1%, and has increased its payouts by 74.5% over the past decade. Gilead Sciences appears to be an attractive dividend payer for long-term investors.
Gilead Sciences (GILD - Free Report) closed at $157.48 in the latest trading session, marking a +2.57% move from the prior day. This move outpaced the S&P 500's daily gain of 0.33%. At the same time, the Dow added 1.08%, and the tech-heavy Nasdaq gained 0.08%.
Shares of the HIV and hepatitis C drugmaker have appreciated by 3.97% over the course of the past month, outperforming the Medical sector's loss of 0.15%, and the S&P 500's gain of 1.41%.
Analysts and investors alike will be keeping a close eye on the performance of Gilead Sciences in its upcoming earnings disclosure. The company is expected to report EPS of $2.16, down 12.55% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $7.81 billion, up 0.59% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$0.47 per share and a revenue of $30.76 billion, indicating changes of -105.77% and +4.47%, respectively, from the former year.
Investors should also note any recent changes to analyst estimates for Gilead Sciences. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 1.52% upward. At present, Gilead Sciences boasts a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 153, which puts it in the bottom 38% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Key Takeaways Gilead partners with Vir Biotechnology to develop three novel T-cell engagers targeting solid tumorsVir can receive $90 million upfront, up to $45 million in near-term milestones and $1.74 billion more.Gilead's oncology expansion faces cell therapy competition, while deal costs pressure near-term profitability. Gilead Sciences, Inc. (GILD - Free Report) recently entered into a collaboration and license agreement with Vir Biotechnology, Inc. (VIR - Free Report) to discover and engineer three novel PRO-XTEN dual-masked T-cell engager (TCE) development candidates targeting selected solid tumor-associated antigens.
Per the deal, Gilead will have an exclusive license to develop and commercialize the novel TCEs.
The collaboration gives Gilead an opportunity to develop three potential cancer therapies targeting selected solid tumor-associated antigens, broadening its next-generation immunotherapy portfolio.
We note that GILD is looking to strengthen its oncology franchise and diversify its revenue base, which is highly concentrated on HIV business.
Under the financial terms of the agreement, Vir Biotechnology will be eligible to receive up to $135 million in total upfront and near-term preclinical milestone payments, consisting of $90 million in upfront consideration and up to $45 million in potential near-term preclinical milestones. Gilead could also owe up to $1.74 billion in additional development, regulatory and commercial milestone payments, along with tiered royalties on net sales. These payments depend on the achievement of specified milestones and do not represent guaranteed costs payable immediately.
Gilead’s oncology portfolio, comprising the Cell Therapy franchise and breast cancer drug Trodelvy, has diversified its overall business. The breast cancer drug Trodelvy has performed well since its approval.
Trodelvy, a first-in-class Trop-2-directed antibody-drug conjugate (ADC), is approved in several countries for second-line or later metastatic triple-negative breast cancer and for certain patients with pre-treated HR+/HER2- metastatic breast cancer.
GILD has multiple ongoing studies aimed at further expanding Trodelvy’s label.
However, the Cell Therapy franchise, comprising Yescarta and Tecartus, is currently under pressure due to competitive headwinds in the United States and Europe that are expected to continue.
Gilead’s recent aggressive dealmaking strategy, including the acquisitions of Arcellx and Tubulis, underscores its commitment to diversifying beyond its core HIV franchise and expanding into higher-growth oncology and immunology markets.
Launch preparations are underway for anito-cel (added from Arcellx acquisition), which has a Dec. 23 regulatory action date for heavily pretreated relapsed or refractory multiple myeloma.
The Tubulis acquisition added next-generation antibody-drug conjugate (ADC) assets, including GS-8824, a NaPi2b-directed topoisomerase-I inhibitor ADC, and a platform to develop novel ADCs, to GILD’s pipeline.
Competition for GILD’s Oncology Business Datroway (datopotamab deruxtecan), developed by AstraZeneca (AZN - Free Report) and Daiichi Sankyo, is also a TROP2-directed ADC.
It is approved in several countries for the treatment of adult patients with unresectable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy.
AstraZeneca and Daiichi Sankyo entered into a global collaboration agreement in March 2019 to jointly develop and commercialize Enhertu (trastuzumab deruxtecan), followed by a similar agreement for Datroway in July 2020. Daiichi Sankyo retains exclusive rights to both ADCs in Japan.
AstraZeneca and Daiichi Sankyo recently entered into a clinical collaboration agreement with Summit Therapeutics Inc. to evaluate Datroway in combination with ivonescimab across multiple tumour types, including lung and breast cancers. The companies intend to begin with a phase III study in first-line TNBC.
In May 2026, AstraZeneca and Daiichi Sankyo announced that the Datroway has been approved in the United States for the treatment of adult patients with unresectable or mTNBC who are not candidates for PD-1/PD-L1 inhibitor therapy.
In the Cell therapy space, GILD’s therapies face competition from Bristol Myers’ (BMY - Free Report) Breyanzi.
Breyanzi is a CD19-directed CAR T cell therapy with a 4-1BB costimulatory domain, which enhances the expansion and persistence of the CAR T cells. It is approved for multiple blood cancers and is a top contributor to BMY’s top line.
BMY is also evaluating arlocabtagene autoleucel (arlo-cel; BMS-986393) in heavily pretreated patients with relapsed and refractory multiple myeloma (RRMM).
GILD’s Price Performance, Valuation and EstimatesShares of GILD have gained 25.1% year to date against the industry’s decline of 0.3%.
Image Source: Zacks Investment Research
Going by the price/earnings ratio, GILD’s shares currently trade at 19.9X forward earnings, higher than its mean of 12.32X and the large-cap pharma industry’s 17.92X.
Image Source: Zacks Investment Research
Over the past 30 days, the consensus estimate for 2026 loss per share has narrowed to 47 cents from 59 cents. The earnings estimate for 2027 has increased to $9.87 per share from $9.58 over the same period.
Image Source: Zacks Investment Research
While Gilead’s recent aggressive dealmaking strategy strengthens its long-term pipeline and growth potential, the sizable upfront payments and integration-related costs are pressuring near-term profitability.
The significant rotation in the AI trade, particularly in neoclouds like CoreWeave (CRVW), is something Dan Deming believes opens the door to new trading opportunities. He sees Merck (MRK) leading a stabilizing healthcare sector, Gilead Sciences (GILD) as a stock "poised to continue upward price action," and Exxon Mobil (XOM) as a high-liquid name in a booming energy trade.
Gilead Sciences (GILD - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Over the past month, shares of this HIV and hepatitis C drugmaker have returned +4%, compared to the Zacks S&P 500 composite's +2.1% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which Gilead falls in, has lost 3.7%. The key question now is: What could be the stock's future direction?
While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.
Earnings Estimate RevisionsHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
Gilead is expected to post earnings of $2.16 per share for the current quarter, representing a year-over-year change of -12.6%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.3%.
The consensus earnings estimate of -$0.47 for the current fiscal year indicates a year-over-year change of -105.8%. This estimate has changed +1.5% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $9.91 indicates a change of +0% from what Gilead is expected to report a year ago. Over the past month, the estimate has changed +0.4%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Gilead is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth ForecastWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
In the case of Gilead, the consensus sales estimate of $7.81 billion for the current quarter points to a year-over-year change of +0.6%. The $30.76 billion and $32.64 billion estimates for the current and next fiscal years indicate changes of +4.5% and +6.1%, respectively.
Last Reported Results and Surprise HistoryGilead reported revenues of $7.8 billion in the last reported quarter, representing a year-over-year change of +10.2%. EPS of -$6.75 for the same period compares with $2.01 a year ago.
Compared to the Zacks Consensus Estimate of $7.37 billion, the reported revenues represent a surprise of +5.92%. The EPS surprise was +4.53%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.
ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Gilead is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Gilead. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
Vir Biotechnology Inc. (NASDAQ:VIR) announced a major collaboration with Gilead Sciences Inc. (NASDAQ:GILD) to create three novel T-cell engagers (TCEs) aimed at treating solid tumors.
The agreement grants Gilead exclusive rights to develop and commercialize these new therapies, potentially revolutionizing treatments for cancers with significant unmet needs.
• Vir Biotechnology stock is trending lower. Why is VIR stock trading lower?
Leveraging Advanced TechnologiesVir Biotechnology will utilize its expertise in protein engineering and its proprietary dAIsY platform, which employs AI for the rapid optimization of TCEs.
Additionally, the company will implement its PRO-XTEN masking technology. These combined efforts aim to develop TCEs that exhibit potent anti-tumor activity alongside a broad therapeutic index.
Read Next
Financial Terms and MilestonesUnder the agreement’s terms, Vir is responsible for the discovery and optimization of the candidates. In return, the company will receive up to $135 million in upfront and near-term preclinical milestone payments.
This includes $65 million in cash and a $25 million equity investment by Gilead at a 30% premium.
Furthermore, Vir stands to gain up to $1.74 billion in subsequent development, regulatory, and commercial milestones.
The deal also includes tiered royalties on net sales, ranging from high single digits to low double digits.
In February, Vir Biotechnology collaborated with Astellas Pharma Inc. to advance VIR-5500, an investigational treatment for prostate cancer. Vir Biotechnology received $335 million in upfront and is expected to receive near-term milestone payments, including $240 million in cash and $75 million in equity investment at a 50% premium.
GILD/VIR Price Action: Gilead Sciences shares were up 2.67% at $151.87, and Vir Biotechnology shares were down 1.60% at $10.44 at the time of publication on Wednesday, according to Benzinga Pro data.
Photo via Shutterstock
Read Next
Market News and Data brought to you by Benzinga APIs
RHS Financial LLC increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 584.1% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 24,451 shares of the biopharmaceutical company’s stock after purchasing an additional 20,877 shares during the period. Gilead Sciences accounts for approximately 1.1% of RHS Financial LLC’s investment portfolio, making the stock its 27th biggest position. RHS Financial LLC’s holdings in Gilead Sciences were worth $3,644,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in Gilead Sciences during the 2nd quarter worth approximately $15,393,785,000. Legal & General Group Plc acquired a new position in shares of Gilead Sciences during the second quarter valued at approximately $1,316,606,000. Deutsche Bank AG acquired a new position in shares of Gilead Sciences during the second quarter valued at approximately $918,387,000. Jupiter Topco LLC purchased a new position in shares of Gilead Sciences in the second quarter valued at approximately $448,021,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Gilead Sciences in the second quarter valued at approximately $398,905,000. 83.67% of the stock is owned by hedge funds and other institutional investors.
Insiders Place Their Bets In related news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $144.22, for a total value of $432,660.00. Following the completion of the sale, the insider owned 116,684 shares of the company’s stock, valued at approximately $16,828,166.48. This trade represents a 2.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $145.29, for a total value of $435,870.00. Following the transaction, the chief financial officer owned 164,096 shares in the company, valued at approximately $23,841,507.84. The trade was a 1.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 105,000 shares of company stock valued at $14,940,540. Insiders own 0.30% of the company’s stock.
Gilead Sciences Stock Down 1.7% Shares of NASDAQ GILD opened at $147.92 on Wednesday. Gilead Sciences, Inc. has a 12-month low of $114.02 and a 12-month high of $157.29. The stock has a market cap of $183.41 billion, a PE ratio of -55.40 and a beta of 0.31. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. The company has a 50-day moving average of $145.77 and a 200 day moving average of $136.87. Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. During the same period last year, the company posted $2.01 EPS. The business’s revenue was up 10.6% on a year-over-year basis. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post -0.47 EPS for the current fiscal year.
Gilead Sciences Announces Dividend The business also recently declared a quarterly dividend, which was paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th were given a $0.82 dividend. The ex-dividend date was Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. Gilead Sciences’s dividend payout ratio is -122.85%.
Key Gilead Sciences News Here are the key news stories impacting Gilead Sciences this week:
Positive Sentiment: Analysts remain bullish on Gilead, highlighting the company among attractive healthcare stocks. The positive view reflects Gilead’s HIV, liver-disease and oncology franchises, as well as its longer-term growth prospects. Analysts Are Bullish on These Healthcare Stocks: BioNTech SE (BNTX), Gilead Sciences (GILD) Positive Sentiment: Bank of America said survey results support a favorable long-term outlook for Yeztugo, Gilead’s HIV-prevention drug. Strong adoption potential could provide an additional growth driver for the company’s HIV portfolio. Gilead Sciences’ Yeztugo Survey Supports Long-Term Growth Outlook, BofA Says Positive Sentiment: Erste Group Bank modestly raised its FY2027 EPS forecast for Gilead to $9.90 from $9.88, signaling confidence in the company’s future profitability. Erste Group Bank Raises Gilead Sciences EPS Estimate Neutral Sentiment: Recent comparisons with GRAIL and Vertex Pharmaceuticals provide valuation and operating-context analysis but do not identify a specific new catalyst for GILD. Contrasting GRAIL and Gilead Sciences Gilead Sciences versus Vertex Pharmaceuticals Negative Sentiment: Gilead’s upcoming third-quarter earnings report is expected to show a double-digit year-over-year EPS decline. That forecast is weighing on sentiment despite optimism about the company’s longer-term pipeline and product growth. Earnings Preview: What to Expect From Gilead Sciences’ Report Analysts Set New Price Targets A number of brokerages have recently issued reports on GILD. Royal Bank Of Canada lifted their price target on Gilead Sciences from $123.00 to $126.00 and gave the stock a “sector perform” rating in a research note on Thursday, October 8th. Barclays dropped their price target on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 29th. Leerink Partners downgraded Gilead Sciences from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $146.00 to $127.00 in a research note on Tuesday, July 21st. HSBC raised their price objective on Gilead Sciences from $155.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Finally, Bank of America reaffirmed a “buy” rating and set a $164.00 target price on shares of Gilead Sciences in a research note on Monday. Twenty-three research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and an average target price of $159.33.
Read Our Latest Analysis on Gilead Sciences
Gilead Sciences Profile (Free Report)
Gilead Sciences, Inc (NASDAQ: GILD) is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. Its research and commercial activities focus primarily on virology, including HIV, hepatitis B and hepatitis C, as well as oncology, inflammation and other areas of significant unmet medical need.
Gilead’s portfolio includes HIV treatments such as Biktarvy, Descovy, Genvoya and Sunlenca; hepatitis therapies including Epclusa, Harvoni and Vemlidy; and Veklury (remdesivir), an antiviral used to treat COVID-19 in certain patients.
Featured Stories Five stocks we like better than Gilead Sciences A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be? Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity? Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
Gilead Sciences (NASDAQ:GILD – Get Free Report) and GRAIL (NASDAQ:GRAL – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.
Valuation and Earnings This table compares Gilead Sciences and GRAIL”s gross revenue, earnings per share and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gilead Sciences $29.44 billion 6.37 $8.51 billion ($2.67) -56.62 GRAIL $147.17 million 42.67 -$408.35 million ($9.75) -14.42 Gilead Sciences has higher revenue and earnings than GRAIL. Gilead Sciences is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks. Risk & Volatility Gilead Sciences has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500. Comparatively, GRAIL has a beta of 2.83, meaning that its share price is 183% more volatile than the S&P 500.
Profitability This table compares Gilead Sciences and GRAIL’s net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets Gilead Sciences -10.64% -2.11% -0.75% GRAIL -236.95% -15.88% -14.02% Institutional and Insider Ownership 83.7% of Gilead Sciences shares are held by institutional investors. 0.3% of Gilead Sciences shares are held by company insiders. Comparatively, 1.8% of GRAIL shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Recommendations This is a breakdown of current ratings and recommmendations for Gilead Sciences and GRAIL, as provided by MarketBeat.com.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gilead Sciences 0 6 23 0 2.79 GRAIL 1 6 5 0 2.33 Gilead Sciences currently has a consensus price target of $159.26, suggesting a potential upside of 5.35%. GRAIL has a consensus price target of $102.70, suggesting a potential downside of 26.95%. Given Gilead Sciences’ stronger consensus rating and higher probable upside, research analysts plainly believe Gilead Sciences is more favorable than GRAIL.
Summary Gilead Sciences beats GRAIL on 10 of the 14 factors compared between the two stocks.
(Get Free Report)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
About GRAIL (Get Free Report)
GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
Gilead Sciences (GILD - Free Report) closed at $151.17 in the latest trading session, marking a +2.77% move from the prior day. The stock outperformed the S&P 500, which registered a daily gain of 0.6%. Elsewhere, the Dow gained 0.83%, while the tech-heavy Nasdaq added 0.64%.
The stock of HIV and hepatitis C drugmaker has risen by 1.58% in the past month, leading the Medical sector's loss of 1.97% and the S&P 500's gain of 1.34%.
Analysts and investors alike will be keeping a close eye on the performance of Gilead Sciences in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $2.14, marking a 13.36% fall compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $7.81 billion, indicating a 0.51% increase compared to the same quarter of the previous year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$0.48 per share and a revenue of $30.76 billion, signifying shifts of -105.89% and +4.47%, respectively, from the last year.
Investors might also notice recent changes to analyst estimates for Gilead Sciences. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.57% higher. Gilead Sciences is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 177, putting it in the bottom 29% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
What happened Gilead Sciences, Inc. (NASDAQ: GILD) said Chairman & CEO and director Daniel Patrick O'Day sold 15,000 shares on 2026-10-01. The stock went at prices from $147.72 to $148.63 a share, for about $2.22 million total. The filing leaves O'Day with 566,683 shares after the trade.
The filing lists the stock as common stock and breaks the sale into 12,000 shares at $147.719 and 3,000 shares at $148.6265. Those line items sit inside the price range given in the main disclosure. The report was filed on 2026-10-02, the day after the trade date.
Key numbers Metric Latest Change Source Shares sold 15,000 shares SEC Form 4 Sale price per share $147.72 to $148.63 per share SEC Form 4 Total sale value about $2.22 million SEC Form 4 Shares held after sale 566,683 shares SEC Form 4 Sale as share of pre-sale holding 2.6% Calculated from SEC Form 4 Read more: Gilead Sciences (GILD) stock analysis and investment case Why it matters OptimistFi's case is that Gilead converts a high-margin, specialty-drug revenue base into large, stable free cash flow and shareholder returns. This filing does not change that thesis. Using the post-sale holding and the shares sold, O'Day's pre-sale position was 581,683 shares, so the sale was about 2.6% of that stake. The remaining 566,683 shares keep O'Day exposed to the same stock. For investors, that is a small trim relative to the remaining holding.
The strongest caveat is the Rule 10b5-1 trading plan, which the filing says was adopted on February 25, 2026. That pre-set structure limits how much investors can read into the timing, price range or size of the sale. It also means the trade reads as a preset ownership move. The plan date, not the sale date, is the main limiter on reading intent into the trade.
Browse: stock research on every company OptimistFi covers
What's next Gilead's next quarterly report is the next scheduled test. A report that keeps cash generation and shareholder returns on track would support OptimistFi's case, while weaker results would pressure it. Until then, the filing is mainly a record that O'Day remained a sizable holder after a planned sale. That matters for readers who track insider ownership, but it leaves the operating outlook to the next report. For now, the form is a baseline, not a business verdict.
More from OptimistFi GILD stock: the Gilead Sciences thesis, its status and the next test to watch Century Therapeutics, Inc. (NASDAQ: IPSC) Adds Two CNTY-813 Batches Applied Digital Corporation (NASDAQ: APLD) Brings 250 MW Online ON Semiconductor Corporation (NASDAQ: ON) Cuts Its Deal Cost by 19% Stock research on every company OptimistFi covers Latest stock research and investment-case updates OptimistFi: evidence-first equity research Sources SEC Form 4 — Form 4 for Daniel Patrick O'Day, filed 2026-10-02. Read the full OptimistFi thesis on Gilead Sciences, Inc.: https://optimistfi.com/stocks/GILD
See what would break the Gilead Sciences, Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full Gilead Sciences, Inc. investment case, its status and the next test to watch live on the Gilead Sciences, Inc. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
In the latest close session, Gilead Sciences (GILD - Free Report) was down 1.87% at $144.74. The stock's change was less than the S&P 500's daily gain of 0.73%. Elsewhere, the Dow saw an upswing of 0.49%, while the tech-heavy Nasdaq appreciated by 1.19%.
Coming into today, shares of the HIV and hepatitis C drugmaker had lost 2.46% in the past month. In that same time, the Medical sector lost 3.74%, while the S&P 500 gained 0.55%.
Analysts and investors alike will be keeping a close eye on the performance of Gilead Sciences in its upcoming earnings disclosure. On that day, Gilead Sciences is projected to report earnings of $2.15 per share, which would represent a year-over-year decline of 12.96%. Alongside, our most recent consensus estimate is anticipating revenue of $7.79 billion, indicating a 0.3% upward movement from the same quarter last year.
GILD's full-year Zacks Consensus Estimates are calling for earnings of -$0.48 per share and revenue of $30.74 billion. These results would represent year-over-year changes of -105.89% and +4.4%, respectively.
Investors should also take note of any recent adjustments to analyst estimates for Gilead Sciences. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been a 0.19% rise in the Zacks Consensus EPS estimate. Gilead Sciences is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 181, which puts it in the bottom 27% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
You are now leaving Barron's websiteBy clicking on the “Proceed” button below, you will be redirected to a third-party website owned and operated by Hong Kong Tiimoot Information Technology Co., Limited. (“HKT”), which is located in Hong Kong. That website operates independently from Barron's and Barron's does not control the website. The privacy practices of HKT are subject to its Privacy Statement, so please read it closely. We are not responsible for HKT's privacy or other data-related practices.
Gilead Sciences (GILD - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Over the past month, shares of this HIV and hepatitis C drugmaker have returned -0.4%, compared to the Zacks S&P 500 composite's -0.4% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which Gilead falls in, has lost 0.7%. The key question now is: What could be the stock's future direction?
While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.
Revisions to Earnings EstimatesHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
Gilead is expected to post earnings of $2.15 per share for the current quarter, representing a year-over-year change of -13%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.
The consensus earnings estimate of -$0.48 for the current fiscal year indicates a year-over-year change of -105.9%. This estimate has changed +0.2% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $9.87 indicates a change of +0% from what Gilead is expected to report a year ago. Over the past month, the estimate has remained unchanged.
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Gilead.
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth ForecastWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
In the case of Gilead, the consensus sales estimate of $7.79 billion for the current quarter points to a year-over-year change of +0.3%. The $30.74 billion and $32.61 billion estimates for the current and next fiscal years indicate changes of +4.4% and +6.1%, respectively.
Last Reported Results and Surprise HistoryGilead reported revenues of $7.8 billion in the last reported quarter, representing a year-over-year change of +10.2%. EPS of -$6.75 for the same period compares with $2.01 a year ago.
Compared to the Zacks Consensus Estimate of $7.37 billion, the reported revenues represent a surprise of +5.92%. The EPS surprise was +4.53%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.
ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Gilead is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Gilead. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
Gilead Sciences (GILD - Free Report) ended the recent trading session at $149.45, demonstrating a -1.21% change from the preceding day's closing price. This change lagged the S&P 500's daily loss of 0.25%. Elsewhere, the Dow lost 0.86%, while the tech-heavy Nasdaq added 0.24%.
Coming into today, shares of the HIV and hepatitis C drugmaker had gained 0.91% in the past month. In that same time, the Medical sector lost 1.01%, while the S&P 500 lost 0.42%.
Analysts and investors alike will be keeping a close eye on the performance of Gilead Sciences in its upcoming earnings disclosure. The company's earnings per share (EPS) are projected to be $2.15, reflecting a 12.96% decrease from the same quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $7.79 billion, indicating a 0.3% upward movement from the same quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$0.48 per share and a revenue of $30.74 billion, signifying shifts of -105.89% and +4.4%, respectively, from the last year.
Investors should also take note of any recent adjustments to analyst estimates for Gilead Sciences. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 2.2% lower. Right now, Gilead Sciences possesses a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 180, which puts it in the bottom 27% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the twenty-nine research firms that are covering the stock, MarketBeat.com reports. Five research analysts have rated the stock with a hold rating, twenty-three have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $158.78.
A number of brokerages have recently weighed in on GILD. Barclays reduced their price target on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 29th. Cantor Fitzgerald reissued an “overweight” rating and set a $155.00 target price on shares of Gilead Sciences in a report on Wednesday, August 5th. Zacks Research upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 31st. Morgan Stanley decreased their price target on Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating for the company in a research note on Monday, July 27th. Finally, Truist Financial lowered their price target on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th.
Read Our Latest Research Report on GILD
Insider Activity In other news, CEO Daniel O’Day sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $148.64, for a total transaction of $2,229,600.00. Following the completion of the transaction, the chief executive officer owned 577,133 shares in the company, valued at approximately $85,785,049.12. This trade represents a 2.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $145.29, for a total transaction of $435,870.00. Following the completion of the transaction, the chief financial officer directly owned 164,096 shares in the company, valued at $23,841,507.84. This represents a 1.80% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 105,000 shares of company stock valued at $14,616,390 over the last quarter. Insiders own 0.30% of the company’s stock. Institutional Trading of Gilead Sciences A number of large investors have recently added to or reduced their stakes in GILD. BlackRock Inc. acquired a new stake in Gilead Sciences during the 2nd quarter valued at $15,393,785,000. State Street Corp boosted its stake in Gilead Sciences by 2.3% in the second quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock worth $7,734,099,000 after purchasing an additional 1,357,967 shares in the last quarter. Norges Bank acquired a new position in Gilead Sciences in the fourth quarter worth $2,617,152,000. Invesco Ltd. grew its holdings in shares of Gilead Sciences by 2.9% during the fourth quarter. Invesco Ltd. now owns 15,584,341 shares of the biopharmaceutical company’s stock worth $1,912,822,000 after purchasing an additional 444,660 shares during the last quarter. Finally, Amundi grew its holdings in shares of Gilead Sciences by 10.7% during the first quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock worth $1,468,836,000 after purchasing an additional 1,018,976 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.
Gilead Sciences Price Performance Shares of GILD opened at $150.93 on Friday. Gilead Sciences has a one year low of $108.46 and a one year high of $157.29. The stock’s fifty day moving average is $141.81 and its 200-day moving average is $136.45. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The firm has a market capitalization of $187.15 billion, a price-to-earnings ratio of -56.53 and a beta of 0.33.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last announced its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. The firm had revenue of $7.80 billion during the quarter, compared to analyst estimates of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. Gilead Sciences’s revenue was up 10.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.01 EPS. Equities analysts anticipate that Gilead Sciences will post -0.48 EPS for the current year.
Gilead Sciences Announces Dividend The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be paid a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 annualized dividend and a yield of 2.2%. Gilead Sciences’s dividend payout ratio (DPR) is currently -122.85%.
(Get Free Report)
Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company’s research focuses primarily on virology, oncology, inflammation and related areas, with products serving patients in the United States and international markets.
Gilead is best known for its HIV treatments, including Biktarvy, Genvoya, Descovy and other antiretroviral therapies. Its portfolio also includes medicines for viral hepatitis, such as Epclusa and Vemlidy, and Veklury (remdesivir), an antiviral treatment for COVID-19.
Recommended Stories Five stocks we like better than Gilead Sciences Costco Ends Its Fiscal Year on a High Note, Eyes Big Expansion Cracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem Oracle’s Force Majeure Notice Exposes a Bigger Problem for the AI Build-Out Oil May Be Stronger Than It Looks—And Diamondback Is on Sale
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
Today we highlight a discovery with potentially important implications for future Alzheimer's research and treatments. We also report on an experimental Gilead therapy showing great promise against a difficult-to-treat form of blood cancer, and an interesting new method for studying cells linked to age-related disorders.
EFFECTS OF ALZHEIMER’S GENE MIGHT BE REVERSIBLE
Scientists studying the strongest genetic risk factor for Alzheimer's disease say they have new clues to how it works and how its damaging effects on the brain could potentially be reversed.
Doctors have long known that the brain’s blood vessels deteriorate with Alzheimer’s disease, particularly in people with the APOE4 gene, but the underlying mechanisms have remained unclear.
In fact, APOE4 damages the brain's blood vessels and promotes the buildup of abnormal proteins, researchers at the Icahn School of Medicine at Mount Sinai in New York have discovered.
It does so by causing pericytes, cells that normally stabilize small blood vessels, to transform into scar-forming cells that thicken the vessels and increase the accumulation of abnormal, misfolded protein clumps known as amyloid, the target of current treatments. These conditions can compromise the flow of blood to the brain, leading to brain damage.
Blocking a protein called TGF-beta that is involved in tissue cell activity and repair protected the pericytes and reversed APOE4-associated cerebrovascular degeneration in mice, the researchers also discovered.
Their findings are reported in two separate papers in Cell and Cell Stem Cell.
“Damage to the brain’s blood vessels is not simply a late consequence of Alzheimer’s disease; it is a biologically active process caused by APOE4 that may be reversible,” Joel Blanchard, who co-authored both papers, said in a statement.
“These findings reveal new therapeutic targets for preserving vascular function and limiting amyloid accumulation.”
GILEAD THERAPY SHOWS PROMISE IN MULTIPLE MYELOMA TRIAL
An investigational CAR T-cell therapy from Gilead Sciences (GILD.O) led to deep and durable responses in people with hard-to-treat or recurrent multiple myeloma in an early-stage trial, researchers reported in The New England Journal of Medicine.
Phase 1 trials are designed to test safety, not efficacy, so the promising results will require confirmation in larger trials.
But all 38 patients who received anitocabtagene autoleucel (anito-cel) responded to the treatment, and nearly 80% achieved a complete response, meaning no detectable cancer, the researchers said.
Many of the patients experienced lasting benefits, with more than half showing no sign of disease progression two years later and 65% still alive after three years.
Serious immune-related and neurological side effects were uncommon, and no delayed neurological complications were reported.
Anito-cel is a so-called B-cell maturation antigen, or BCMA-targeted CAR T-cell therapy, in which a patient's immune system T cells are removed and engineered in a laboratory to locate and destroy cells expressing BCMA — a protein found in high amounts on the surface of multiple myeloma cells — before being reinfused.
“These were great results for a Phase 1 trial,” study leader Dr. Michael Bishop of UChicago Medicine said in a statement.
“Even at a low dose of anito-cel, we were seeing complete responses in the majority of patients right off the bat, and not a single patient developed severe toxicities.”
Anito-cel is currently being evaluated in Phase 2 and Phase 3 clinical trials to confirm these findings in larger populations of patients with multiple myeloma, the researchers said.
FINDING OLD CELLS THAT DON’T DIE WHEN THEY SHOULD
Researchers have found a noninvasive way to identify and study cells in the body that contribute to age-related disorders such as cancer, tissue degeneration, and inflammatory diseases.
These so-called senescent cells have stopped dividing and growing but for some reason have not died, as would be expected of old cells. Instead, they undergo significant changes to their shape, metabolic processes, and gene activity.
Earlier methods of studying these cells would destroy them, the researchers noted in a report of the study in Nature Aging.
Using an analytical technique known as Raman microscopy, which reveals the biochemical composition of cells without harming them, and analyzing individual cells’ genetic activity, the researchers were able to identify unique “barcodes” of senescent cells.
The study was done in mouse cells. The researchers are now working on adapting it for use with human tissue.
“You can imagine that one day we may develop an endoscope that can look inside your body and identify cellular senescence,” Jeon Woong Kang of MIT, one of the senior authors of the study, said in a statement.
Study leader Peter So of MIT noted that senescence "is not just a pathological condition.”
While it can also contribute to sagging skin and muscle weakness in aging individuals, cellular senescence plays critical beneficial roles in embryonic development and tissue regeneration, the researchers noted.
The research is part of a National Institutes of Health initiative called the Cellular Senescence Network.
“The idea behind the NIH Cellular Senescence Network is to take a very comprehensive approach to understand senescence and identify senescent cells, because it plays a role in so many normal physiological conditions and many pathological conditions,” So said.
(To receive the full newsletter in your inbox for free sign up here)
Envestnet Asset Management Inc. reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 5.9% in the second quarter, according to its most recent filing with the SEC. The fund owned 1,749,512 shares of the biopharmaceutical company’s stock after selling 109,500 shares during the period. Envestnet Asset Management Inc. owned approximately 0.14% of Gilead Sciences worth $221,033,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new stake in Gilead Sciences in the second quarter worth approximately $15,393,785,000. State Street Corp lifted its holdings in shares of Gilead Sciences by 2.3% in the 2nd quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock worth $7,734,099,000 after acquiring an additional 1,357,967 shares during the last quarter. Norges Bank bought a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $2,617,152,000. Invesco Ltd. boosted its stake in shares of Gilead Sciences by 2.9% in the 4th quarter. Invesco Ltd. now owns 15,584,341 shares of the biopharmaceutical company’s stock valued at $1,912,822,000 after purchasing an additional 444,660 shares in the last quarter. Finally, Amundi boosted its stake in shares of Gilead Sciences by 10.7% in the 1st quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock valued at $1,468,836,000 after purchasing an additional 1,018,976 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity at Gilead Sciences In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $145.29, for a total value of $435,870.00. Following the completion of the transaction, the chief financial officer directly owned 164,096 shares in the company, valued at approximately $23,841,507.84. This represents a 1.80% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $145.02, for a total transaction of $725,100.00. Following the completion of the sale, the director directly owned 10,066 shares of the company’s stock, valued at approximately $1,459,771.32. This represents a 33.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 105,000 shares of company stock valued at $14,616,390 over the last 90 days. Company insiders own 0.30% of the company’s stock.
Analyst Upgrades and Downgrades A number of equities analysts recently commented on the stock. Royal Bank Of Canada lifted their target price on shares of Gilead Sciences from $120.00 to $123.00 and gave the stock a “sector perform” rating in a research report on Wednesday, August 5th. Truist Financial cut their price target on shares of Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a research report on Tuesday, July 7th. HSBC raised their price objective on Gilead Sciences from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Morgan Stanley lowered their target price on Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating for the company in a research note on Monday, July 27th. Finally, Weiss Ratings upgraded Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, September 14th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $158.78. Check Out Our Latest Stock Analysis on GILD
Gilead Sciences Price Performance GILD stock opened at $149.69 on Friday. The firm’s 50-day moving average price is $141.48 and its two-hundred day moving average price is $136.35. Gilead Sciences, Inc. has a 12-month low of $108.46 and a 12-month high of $157.29. The stock has a market capitalization of $185.61 billion, a price-to-earnings ratio of -56.06 and a beta of 0.33. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The company had revenue of $7.80 billion for the quarter, compared to the consensus estimate of $7.40 billion. During the same quarter in the previous year, the business earned $2.01 EPS. Gilead Sciences’s revenue was up 10.6% compared to the same quarter last year. As a group, equities analysts predict that Gilead Sciences, Inc. will post -0.48 earnings per share for the current year.
Gilead Sciences Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be paid a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.2%. Gilead Sciences’s payout ratio is -122.85%.
Gilead Sciences Company Profile (Free Report)
Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company’s research focuses primarily on virology, oncology, inflammation and related areas, with products serving patients in the United States and international markets.
Gilead is best known for its HIV treatments, including Biktarvy, Genvoya, Descovy and other antiretroviral therapies. Its portfolio also includes medicines for viral hepatitis, such as Epclusa and Vemlidy, and Veklury (remdesivir), an antiviral treatment for COVID-19.
Featured Articles Five stocks we like better than Gilead Sciences Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks Paychex Plunges, Providing the Entry Investors Have Been Waiting For The Case for Buying High-Yield General Mills Just Strengthened SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
MEXICO CITY--(BUSINESS WIRE)-- #Gilead--AIDS Healthcare Foundation (AHF), the world's largest HIV care provider, welcomes a new agreement between Gilead Sciences and the Pan American Health Organization (PAHO) that could expand access to lenacapavir for HIV prevention in 14 countries across Latin America. The agreement represents a positive step toward expanding access in the region and a victory for civil society. AHF was among the first organizations to mobilize around concerns that the initial Gilead-.
Gilead Sciences (GILD - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Shares of this HIV and hepatitis C drugmaker have returned +0.1% over the past month versus the Zacks S&P 500 composite's -2.9% change. The Zacks Medical - Biomedical and Genetics industry, to which Gilead belongs, has gained 1.8% over this period. Now the key question is: Where could the stock be headed in the near term?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Earnings Estimate RevisionsRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.
For the current quarter, Gilead is expected to post earnings of $2.15 per share, indicating a change of -13% from the year-ago quarter. The Zacks Consensus Estimate has changed +0.7% over the last 30 days.
For the current fiscal year, the consensus earnings estimate of -$0.48 points to a change of -105.9% from the prior year. Over the last 30 days, this estimate has changed -0.1%.
For the next fiscal year, the consensus earnings estimate of $9.87 indicates a change of +0% from what Gilead is expected to report a year ago. Over the past month, the estimate has changed +2%.
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Gilead.
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth ForecastWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
In the case of Gilead, the consensus sales estimate of $7.79 billion for the current quarter points to a year-over-year change of +0.3%. The $30.74 billion and $32.6 billion estimates for the current and next fiscal years indicate changes of +4.4% and +6.1%, respectively.
Last Reported Results and Surprise HistoryGilead reported revenues of $7.8 billion in the last reported quarter, representing a year-over-year change of +10.2%. EPS of -$6.75 for the same period compares with $2.01 a year ago.
Compared to the Zacks Consensus Estimate of $7.37 billion, the reported revenues represent a surprise of +5.92%. The EPS surprise was +4.53%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.
ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Gilead is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Gilead. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
Key Takeaways Gilead signed a PAHO deal to expand access to twice-yearly lenacapavir for HIV prevention.The agreement adds a coordinated access pathway across 14 countries outside Gilead's licensing deals.PAHO's Regional Revolving Funds will support coordinated procurement and country-led lenacapavir access. Gilead Sciences (GILD - Free Report) has signed an agreement with the Pan American Health Organization (PAHO) to accelerate access to twice-yearly lenacapavir for HIV prevention across PAHO Member States in Latin America and the Caribbean. The agreement will use PAHO’s Regional Revolving Funds to create a coordinated regional procurement and access pathway, supporting country-led adoption and implementation of long-acting pre-exposure prophylaxis (PrEP). The move expands Gilead’s global access strategy across 14 countries outside its voluntary licensing agreements.
Lenacapavir is marketed as Sunlenca in the United States and the EU for treatment of multidrug-resistant HIV-1 in heavily treatment-experienced adults, in combination with other antiretrovirals. For prevention, it is sold as Yeztugo in the United States and Yeytuo in the EU for PrEP in adults and adolescents weighing at least 35 kilograms who are at increased risk of HIV-1 acquisition.
Lenacapavir stands out for its long-acting profile and distinct mechanism. It is a first-in-class HIV capsid inhibitor designed to interfere with multiple stages of the viral lifecycle, rather than acting at a single stage. Per Gilead, lenacapavir has no known in-vitro cross-resistance with existing antiretroviral classes. The twice-yearly PrEP formulation combines infrequent dosing with a distinct mechanism, potentially broadening prevention choices and addressing adherence challenges.
PAHO Partnership Broadens GILD’s Lenacapavir Market ReachUnder the agreement, PAHO’s Regional Revolving Funds will provide a mechanism for countries across Latin America and the Caribbean to pursue coordinated access to twice-yearly lenacapavir. The framework covers all PAHO Member States, while the immediate access pathway specifically adds 14 countries outside Gilead’s voluntary licensing arrangements: Argentina, Brazil, Chile, Colombia, Costa Rica, Ecuador, El Salvador, Guatemala, Mexico, Panama, Paraguay, Peru, Uruguay and Venezuela.
Year to date, GILD shares have gained 19.1% compared with the industry's growth of 6.8%.
Image Source: Zacks Investment Research
The arrangement complements rather than replaces Gilead’s existing generic-access strategy. The company used different approaches across markets, including voluntary licensing, technology transfer, no-profit supply and regional partnerships. By adding PAHO’s procurement and regional coordination infrastructure, Gilead can potentially reduce fragmentation in market access and help countries move from regulatory and planning stages toward implementation.
For Gilead, broader adoption could expand its HIV prevention franchise while strengthening lenacapavir access infrastructure. It has also expanded its no-profit supply commitment with PEPFAR and the Global Fund to as many as three million people through 2028. GILD’s lenacapavir is already available in 10 sub-Saharan African countries, underscoring the broader rollout underway.
The Latin American opportunity is also relevant because HIV incidence in the region increased 13% between 2010 and 2024, according to Gilead. The company is separately exploring opportunities with Brazil’s Ministry of Health to enable local production of lenacapavir, which could support longer-term regional supply objectives.
Gilead Advances Lenacapavir Across HIV Prevention and TreatmentGilead continues to develop lenacapavir across several clinical programs. In HIV prevention, the registrational phase III PURPOSE 365 study is evaluating once-yearly lenacapavir for HIV prevention and has completed enrollment. Gilead is also developing lenacapavir across several other mid-stage studies evaluating twice-yearly dosing for HIV PrEP in different populations and geographies.
In HIV treatment, Gilead recently received FDA approval for Bixlenvo, a once-daily oral combination of bictegravir and lenacapavir, for the treatment of virologically suppressed adults with HIV. The phase III ISLEND-1 and ISLEND-2 studies are evaluating once-weekly oral islatravir/lenacapavir in virologically suppressed adults with HIV-1. Gilead is also evaluating lenacapavir in several other mid-stage studies for potential HIV treatment applications.
Gilead’s marketed HIV portfolio extends beyond lenacapavir and includes Biktarvy, Descovy and other established antiretroviral therapies. Within the lenacapavir franchise, Yeztugo generated $397 million in sales in the first half of 2026, while Sunlenca is included in GILD’s “Other HIV” category and is not reported separately. Biktarvy and Descovy remain major contributors to the company’s HIV business, generating $7.13 billion and $1.77 billion, respectively, in the first half of 2026. This established commercial base, together with Yeztugo and the broader lenacapavir pipeline, provides Gilead with multiple avenues to extend its HIV franchise.
GILD’s Zacks Rank and Stocks to ConsiderGilead currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Precigen (PGEN - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy), and AC Immune (ACIU - Free Report) and Aldeyra Therapeutics (ALDX - Free Report) , carrying a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Precigen’s 2026 bottom line have improved from a loss of 2 cents to earnings per share of 25 cents. Over the same period, earnings estimates for 2027 have risen from 25 cents to 86 cents. PGEN shares have increased 67.5% year to date.
Precigen’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 108.96%.
Over the past 60 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents. ACIU shares have lost 14.7% year to date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.
Over the past 60 days, loss per share estimates for Aldeyra Therapeutics have narrowed from 43 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 22 cents to 16 cents. ALDX shares have plunged 73.4% year to date.
Aldeyra Therapeutics’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 29.25%.
- 6 Royalty-Free Voluntary Licensing Agreements Aim to Support Potential Manufacturing Readiness and Supply in 120 High-Incidence, Resource-Limited Countries Ahead of Phase 3 PURPOSE 365 Results and Potential Regulatory Approvals -
- Builds On Gilead's Ongoing Commitment to Communities Affected by HIV by Helping Enable Broad, Sustainable Access to Lenacapavir for PrEP -
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has expanded the scope of its six royalty-free voluntary licensing agreements for lenacapavir to include investigational once-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP). The agreements cover 120 high-incidence countries (which are primarily low- and lower-middle-income) and will support manufacturing readiness, technology transfer and future supply planning while the Phase 3 PURPOSE 365 trial is ongoing.
GILEAD ACCELERATES GLOBAL ACCESS PLANNING FOR INVESTIGATIONAL ONCE-YEARLY LENACAPAVIR FOR HIV PREVENTION
Share Key Highlights
If approved, once-yearly lenacapavir could provide a full year of HIV prevention with a single annual dose, expanding prevention choice and helping address barriers that can limit PrEP uptake and persistence. PURPOSE 365 is an ongoing Phase 3 study evaluating the pharmacokinetics, safety and tolerability of investigational once-yearly intramuscular lenacapavir for HIV prevention. Across the Phase 3 PURPOSE 1 and PURPOSE 2 trials, twice-yearly lenacapavir demonstrated unprecedented efficacy for HIV prevention, delivering protection against HIV acquisition across diverse populations while showing superiority to a daily oral PrEP comparator. Gilead is extending its global access model for twice-yearly lenacapavir for HIV prevention to enable broad, sustainable access to multiple generic long-acting HIV prevention options. The expanded agreements represent one of the earliest HIV PrEP access planning efforts undertaken during Phase 3 development and build on Gilead's two decades of experience developing global access pathways for HIV medicines, including unprecedented work for twice-yearly lenacapavir. “Investigational once-yearly lenacapavir for HIV prevention has the potential to add a discreet, extended-duration prevention option that, if approved, could be especially important in high-incidence, resource-limited settings, where people often face significant barriers to accessing and staying on PrEP,” said Johanna Mercier, Chief Commercial & Corporate Affairs Officer, Gilead Sciences. “By establishing voluntary licensing agreements this early in our development process, we are hoping to provide additional time to support manufacturing readiness, healthcare system preparation and community engagement. This supports our goal of helping to ensure that, if approved, the path from innovation to impact has the potential to be shorter, broader and more equitable.”
The expanded agreements have been signed between Gilead and the six voluntary licensing partners who are manufacturing twice-yearly lenacapavir for HIV prevention as PrEP: Dr. Reddy’s Laboratories Limited, Emcure Pharmaceuticals Limited, Eva Pharma for Pharmaceutical Industries S.A.E., Ferozsons Laboratories Limited, Hetero and Mylan Laboratories Limited, a subsidiary of Viatris. These manufacturers were selected based on their demonstrated capabilities in producing complex, sterile injectable medicines and their long-standing experience as voluntary licensing partners with Gilead.
Expanding Choice in HIV Prevention
Despite significant progress in HIV PrEP, substantial gaps in access and uptake remain around the world. An estimated 1.2 million people acquired HIV globally in 2025, underscoring the continued need for additional prevention options that can reach more people who are vulnerable to HIV acquisition. Use of PrEP remains well below global targets: UNAIDS has reported that fewer than 4 million people were using PrEP globally in 2024, far short of the global goal of reaching more than 21 million people.
Expanding choice is critical to helping close the gap in HIV PrEP. People have different needs, preferences, and life circumstances, and barriers such as stigma, healthcare access, and the demands of more frequent dosing or healthcare visits can affect PrEP use. Offering a broader range of options can help more people find an approach that fits their lives, supports discretion, and empowers them to work with their healthcare provider to choose the tool that works best for them.
Once-yearly lenacapavir for PrEP is investigational and has not been approved by any regulatory authority. Its safety and efficacy have not been established. There is no cure for HIV or AIDS.
Building Toward Broad, Sustainable Access to Lenacapavir for HIV Prevention as PrEP
Gilead continues to make progress on its strategy to expand access to twice-yearly lenacapavir for HIV prevention as PrEP. The company recently expanded its partnership commitments with the U.S. State Department through PEPFAR and the Global Fund, increasing the planned reach of its no-profit supply program by 50% – from 2 million people to up to 3 million people through 2028. Lenacapavir is now available in 10 countries across sub-Saharan Africa.
At the same time, licensed manufacturers, governments and implementation partners are actively preparing for upcoming generic availability, reflecting continued momentum toward making twice-yearly HIV prevention medicine, if approved, available to more people in the regions with the greatest unmet need.
Earlier this week, Gilead announced a new agreement with the Pan American Health Organization (PAHO) to accelerate access to twice-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO Member States in Latin America and the Caribbean. Through PAHO’s Regional Revolving Funds, the agreement establishes a coordinated regional pathway to expand access to long-acting HIV prevention and support country-led efforts toward adoption and implementation, as part of the broader efforts to end the epidemic across the region.
About PURPOSE 365
PURPOSE 365 is an ongoing Phase 3, open-label study evaluating the pharmacokinetics, safety and tolerability of investigational once-yearly intramuscular lenacapavir for HIV prevention as PrEP. The study is designed to assess whether a single annual dose of lenacapavir can maintain drug concentrations associated with HIV prevention throughout a 52-week dosing interval, while also evaluating the safety and tolerability of the investigational regimen.
PURPOSE 365 builds on the broader PURPOSE clinical development program, which is evaluating lenacapavir across multiple populations and settings with the goal of expanding prevention choice through long-acting HIV prevention options. The study represents the next phase of Gilead's long-acting HIV prevention research program and is exploring whether reducing dosing frequency to once yearly may help address barriers that can limit uptake and persistence with existing prevention approaches.
By evaluating a once-yearly formulation, PURPOSE 365 aims to generate data that could inform a future HIV prevention option requiring only a single healthcare visit for administration each year. If successful, such an approach could further expand prevention choice and support efforts to reach people who may face challenges with more frequent healthcare interactions or medication schedules.
About Lenacapavir
Twice-yearly lenacapavir is approved in multiple countries as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents who are at risk of HIV acquisition. Lenacapavir is also approved in multiple countries for the treatment of multi-drug-resistant HIV in adults, in combination with other antiretrovirals.
The multi-stage mechanism of action of lenacapavir is distinguishable from other currently approved classes of antiviral agents. While most antivirals act on just one stage of viral replication, lenacapavir is designed to inhibit HIV at multiple stages of its lifecycle and has no known cross resistance exhibited in vitro to other existing drug classes.
Lenacapavir is being evaluated as a long-acting option in multiple ongoing and planned early and late-stage clinical studies in Gilead’s HIV prevention and treatment research program, including a once-yearly injection for HIV prevention. Lenacapavir is being developed as a foundation for potential future HIV therapies with the goal of offering both long-acting oral and injectable options with several dosing frequencies, in combination or as a mono agent, that help address individual needs and preferences of people and communities affected by HIV. The journal Science named lenacapavir its 2024 “Breakthrough of the Year.”
About Gilead HIV
For more than 35 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research. Gilead researchers have developed 14 HIV medications, including the first single-tablet regimen to treat HIV, the first antiretroviral for pre-exposure prophylaxis (PrEP) to help reduce new HIV infections, and the first long-acting injectable HIV treatment medication administered twice-yearly. Our advances in medical research have helped to transform HIV into a treatable, preventable, chronic condition for millions of people.
Gilead is committed to continued scientific innovation to provide solutions for the evolving needs of people affected by HIV around the world. Through partnerships, collaborations and charitable giving, the company also aims to improve education, expand access and address barriers to care, with the goal of ending the HIV epidemic worldwide. Gilead has been repeatedly recognized as one of the top two leading philanthropic funders of HIV-related programs in a report released by Funders Concerned About AIDS.
Discover more about Gilead’s unique collaborations worldwide and the work to help end the HIV epidemic.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. In 2025, Gilead announced a $32 billion investment to further strengthen its U.S. footprint to power the next era of discovery, job creation and public health preparedness – while continuing to invest globally to ensure patients everywhere benefit from its scientific innovation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead’s ability to initiate, progress and complete clinical trials in the anticipated timelines or at all, and the possibility of unfavorable results from ongoing and additional clinical trials, including those involving lenacapavir (such as PURPOSE 365); uncertainties relating to regulatory applications and related filing and approval timelines, including regulatory applications for lenacapavir for PrEP, and the risk that any regulatory approvals, if granted, may be subject to significant limitations on use or subject to withdrawal or other adverse actions by the applicable regulatory authority; the possibility that Gilead may make a strategic decision to discontinue development of lenacapavir for indications currently under evaluation and, as a result, lenacapavir may never be successfully commercialized for such indications; Gilead’s ability to effectively manage, execute and realized the anticipated benefits from the access strategy relating to lenacapavir, including voluntary licensing arrangements and external partnerships relating to lenacapavir; difficulties or unanticipated expenses in connection with such strategy. arrangements and partnerships; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and factors are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements.
Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.
For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on X (@Gilead Sciences) and LinkedIn, or contact Gilead Public Affairs.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced a new agreement with the Pan American Health Organization (PAHO) to accelerate access to twice-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO Member States in Latin America and the Caribbean. Through PAHO’s Regional Revolving Funds, the agreement establishes a coordinated regional pathway to expand access to long-acting HIV prevention and support country-led efforts toward adoption and implementation, as part of the broader efforts to end the epidemic across the region.
Key Highlights
Marks a major milestone within Gilead’s broader global lenacapavir access strategy.Establishes a regional pathway across all PAHO Member States in Latin America and the Caribbean to support broader country-led efforts toward adoption and implementation.Combines PAHO’s regional coordination and procurement capabilities with Gilead’s access strategy to enable sustainable scale-up.The agreement with PAHO builds on Gilead’s longstanding scientific and access efforts to address HIV incidence in Latin America and the Caribbean, where new infections increased by 13% between 2010 and 2024 and gaps in PrEP utilization exist. Those efforts include the PURPOSE 2 trial, which evaluated the efficacy and safety of twice-yearly lenacapavir for PrEP and form part of Gilead's broader commitment to expanding prevention access across the region.
Today’s announcement provides a new access pathway for 14 countries outside of Gilead’s lenacapavir voluntary licensing agreements, complementing existing generic access pathways across the region. Together, these tailored approaches help broaden access to lenacapavir for PrEP across Latin America and the Caribbean. These countries are Argentina, Brazil, Chile, Colombia, Costa Rica, Ecuador, El Salvador, Guatemala, Mexico, Panama, Paraguay, Peru, Uruguay and Venezuela.
“The agreement between Gilead and PAHO reflects our shared commitment to help countries move as quickly as possible from scientific innovation to real-world access to HIV prevention and public health impact,” said Johanna Mercier, Chief Commercial & Corporate Affairs Officer, Gilead Sciences. “For decades, Gilead has worked alongside governments, public health organizations and communities to expand access to HIV innovation around the world. These strategic partnerships are essential to our ambition to help end the HIV epidemic. This agreement demonstrates how collaboration can help accelerate access, support country-led implementation and create the conditions for sustainable scale.”
Beyond the agreement, Gilead intends to continue exploring opportunities to work with PAHO to support country readiness and scale-up of long-acting HIV prevention access, consistent with country priorities and PAHO’s regional public health leadership through the Alliance for the Elimination of HIV in the Americas. The Alliance brings governments, partners and communities together to help accelerate and sustain progress toward ending HIV as a public health issue, including by reaching populations facing the greatest barriers to effective prevention.
“The Americas today have increasingly effective tools to prevent HIV, but these innovations will have an impact only if they reach the people who need them,” said PAHO Director Dr. Jarbas Barbosa. “This initiative is an important step toward reducing gaps in access to lenacapavir, expanding the prevention options available to countries and advancing toward HIV elimination,” he added.
In addition to this agreement, Gilead continues to explore opportunities with the Brazilian Ministry of Health to advance the Ministry’s goal of enabling local production of lenacapavir in Brazil and support long-term regional access objectives through its partnership with PAHO.
The agreement with PAHO forms part of Gilead’s broader global access strategy for lenacapavir, which combines voluntary licensing, technology transfer, no-profit supply, regional access pathways, and partnerships to accelerate access to HIV prevention around the world. Together, these complementary approaches are designed to move countries from planning toward implementation while laying the foundation for sustainable access at scale. These efforts reflect Gilead’s commitment to expanding prevention choice and helping more people benefit from scientific advances in HIV prevention.
Building Toward Broad, Sustainable Access to Lenacapavir for HIV Prevention
Gilead continues to make progress on its strategy to expand access to twice-yearly lenacapavir for HIV prevention as PrEP. The company recently expanded its partnership commitments with the U.S. State Department through PEPFAR and the Global Fund, increasing the planned reach of its no-profit supply program by 50% – from 2 million people to up to 3 million people through 2028. Lenacapavir is now available in 10 countries across sub-Saharan Africa.
At the same time, governments and other partners are actively preparing for upcoming generic availability, reflecting continued momentum toward making twice-yearly HIV prevention medicine, if approved, available to more people in the regions with the greatest unmet need.
About Lenacapavir
Twice-yearly lenacapavir is approved in multiple countries as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents who are at risk of HIV acquisition. Lenacapavir is also approved in multiple countries for the treatment of multi-drug-resistant HIV in adults, in combination with other antiretrovirals.
The multi-stage mechanism of action of lenacapavir is distinguishable from other currently approved classes of antiviral agents. While most antivirals act on just one stage of viral replication, lenacapavir is designed to inhibit HIV at multiple stages of its lifecycle and has no known cross resistance exhibited in vitro to other existing drug classes.
Lenacapavir is being evaluated as a long-acting option in multiple ongoing and planned early and late-stage clinical studies in Gilead’s HIV prevention and treatment research program, including a once-yearly injection for HIV prevention. Lenacapavir is being developed as a foundation for potential future HIV therapies with the goal of offering both long-acting oral and injectable options with several dosing frequencies, in combination or as a mono agent, that help address individual needs and preferences of people and communities affected by HIV. The journal Science named lenacapavir its 2024 “Breakthrough of the Year.”
About Gilead HIV
For more than 35 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research. Gilead researchers have developed 14 HIV medications, including the first single-tablet regimen to treat HIV, the first antiretroviral for pre-exposure prophylaxis (PrEP) to help reduce new HIV infections, and the first long-acting injectable HIV treatment medication administered twice-yearly. Our advances in medical research have helped to transform HIV into a treatable, preventable, chronic condition for millions of people.
Gilead is committed to continued scientific innovation to provide solutions for the evolving needs of people affected by HIV around the world. Through partnerships, collaborations and charitable giving, the company also aims to improve education, expand access and address barriers to care, with the goal of ending the HIV epidemic worldwide. Gilead has been repeatedly recognized as one of the top two leading philanthropic funders of HIV-related programs in a report released by Funders Concerned About AIDS.
Discover more about Gilead’s unique collaborations worldwide and the work to help end the HIV epidemic.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. In 2025, Gilead announced a $32 billion investment to further strengthen its U.S. footprint to power the next era of discovery, job creation and public health preparedness – while continuing to invest globally to ensure patients everywhere benefit from its scientific innovation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead’s ability to effectively manage, execute or realize the anticipated benefits from its global strategy to expand access to lenacapavir for HIV prevention, including twice-yearly lenacapavir, including its partnerships with PAHO, the Global Fund, the U.S. State Department through PEPFAR, and other partners; difficulties or unanticipated challenges in executing the global strategy; Gilead’s ability to initiate, progress and complete clinical trials in the anticipated timelines or at all, and the possibility of unfavorable results from ongoing and additional clinical trials, including those involving lenacapavir (such as PURPOSE 2); uncertainties relating to regulatory applications and related filing and approval timelines, including regulatory applications for lenacapavir for PrEP, and the risk that any regulatory approvals, if granted, may be subject to significant limitations on use or subject to withdrawal or other adverse actions by the applicable regulatory authority; the possibility that Gilead may make a strategic decision to discontinue development of lenacapavir for indications currently under evaluation and, as a result, lenacapavir may never be successfully commercialized for such indications; the risk that physicians and patients may not see the advantages of lenacapavir for PrEP, subject to applicable regulatory approvals; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and factors are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements.
Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.
For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on X (@Gilead Sciences) and LinkedIn, or contact Gilead Public Affairs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260915880261/en/
3 Blue-Chip Stocks Built for a Rotating MarketGilead Sciences NASDAQ: GILD executives outlined plans to expand the company’s HIV prevention and treatment franchises while advancing oncology and inflammation programs, with Chairman and Chief Executive Officer Dan O’Day describing the company as being at an “inflection point in value.”
Speaking at a Morgan Stanley event, O’Day said Gilead has its most robust portfolio of his more than seven years leading the company. He highlighted a cadence of launches across HIV, oncology and inflammation, along with the company’s expectation that it faces no major patent expirations until 2036.
Get Gilead Sciences alerts:
These 3 Cash Flow Machines Provide Stability in Uncertain Markets“We are in a unique position to drive value and growth,” O’Day said, citing Gilead’s operating model, cash flow generation and commitment to industry-leading margins.
HIV prevention growth and Yeztugo launch Chief Commercial and Corporate Affairs Officer Johanna Mercier said the launch of Yeztugo, Gilead’s every-six-month HIV prevention option, has exceeded expectations. The company expects Yeztugo to generate $1 billion in its first full year on the market, according to Mercier.
3 Cash-Flow Machines Investors May Want Heading Into 2026Mercier said the HIV pre-exposure prophylaxis, or PrEP, market is expanding at roughly 14% to 15%, supported by awareness efforts and new treatment choices. Gilead’s total prevention portfolio exceeded $1 billion in quarterly sales, representing an annualized run rate of about $4 billion, she said.
The company is seeing uptake among both people new to PrEP and patients switching from other prevention options. Mercier added that growth through buy-and-bill channels has been faster than anticipated, which she said could signal that clinics are preparing to treat more patients with the six-month regimen.
Gilead reported that more than 70% of patients returned for their second Yeztugo injection, based on the company’s longitudinal claims analysis. Mercier said Gilead is supporting persistence through specialty pharmacy and clinic outreach, digital reminders and a nurse call center program called Ready to Go.
Gilead expects to launch a weekly oral PrEP option in the first quarter of next year. The company is targeting a once-yearly injectable version of Yeztugo for 2028. Mercier said the weekly oral option is expected to draw mainly from Descovy and generic Truvada users, while the six-month injection has a broader potential source of demand, including new PrEP users, daily oral users and users of other long-acting products. Mercier said the Centers for Disease Control and Prevention estimates that 2.2 million people in the U.S. could be candidates for PrEP, compared with a current user base of about 550,000. She said Gilead believes the opportunity could be larger, noting that the U.S. records approximately 13 million sexually transmitted disease diagnoses annually.
Outside the U.S., Mercier said Gilead is working with The Global Fund and the U.S. Department of State in lower- and middle-income countries, particularly in sub-Saharan Africa. In developed markets, she said reimbursement discussions can be challenging because health technology assessment systems often compare newer long-acting therapies with daily generic oral options.
HIV treatment portfolio expansion O’Day and Mercier also described Gilead’s strategy to broaden its HIV treatment business beyond Biktarvy. The company recently launched Bixlenvo, a daily oral treatment intended to help Gilead participate more extensively in the treatment-switch market.
Mercier said Biktarvy remains the leading global HIV treatment, with more than 50% market share and more than two-thirds of the market among treatment-naive patients. However, she said new options are needed for patients seeking to move from Biktarvy to another regimen.
Bixlenvo has indications for virally suppressed patients and for patients on complex regimens, Mercier said. The latter group represents about 5% to 6% of the overall HIV patient population and may be able to reduce multi-pill regimens to one pill daily.
Gilead also expects to launch a weekly oral treatment regimen combining lenacapavir and islatravir next year through its collaboration with Merck. Longer-term development includes potential every-four-month and every-six-month treatment regimens built around lenacapavir and the investigational integrase inhibitor GS-3242.
Mercier said Gilead increased its HIV growth outlook during its second-quarter update to 10% from a prior 8% to 9% range. She attributed a temporary slowing in market growth during the second quarter partly to Affordable Care Act-related effects, but said the company expects the overall HIV market to return to historical growth of 2% to 3% over the next several quarters.
Oncology and inflammation pipeline In oncology, executives highlighted anito-cel, Gilead’s planned cell therapy launch for fourth-line and later multiple myeloma. O’Day described the product profile as potentially “best in disease” and said Gilead is focused on enabling longer treatment-free periods for patients.
The company has fully enrolled a second-line-plus multiple myeloma study, with data expected next year. Mercier said Gilead had just under 180 authorized treatment centers for anito-cel and expects to reach about 200 by its December PDUFA date. She said the company estimates the fourth-line multiple myeloma market represents a $3.5 billion opportunity.
Executives also pointed to Gilead’s antibody-drug conjugate work, including Trodelvy in first-line triple-negative breast cancer and the recently acquired Tubulis ADC platform, initially targeting platinum-resistant ovarian cancer.
In inflammation and immunology, O’Day said Gilead expects Phase II readouts later this year for programs targeting alpha-4 beta-7 and IRAK4. The company also has a STAT6 program and acquired a BCMA T-cell engager, gamgertamig, for potential use in rare diseases where B-cell depletion may be beneficial.
O’Day said Gilead remains open to external collaborations in immunology, similar to its partnerships in HIV, particularly when combinations of differentiated medicines could accelerate patient access.
About Gilead Sciences (NASDAQ:GILD)Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company's research focuses primarily on virology, oncology, inflammation and related areas, with products serving patients in the United States and international markets.
Gilead is best known for its HIV treatments, including Biktarvy, Genvoya, Descovy and other antiretroviral therapies. Its portfolio also includes medicines for viral hepatitis, such as Epclusa and Vemlidy, and Veklury (remdesivir), an antiviral treatment for COVID-19.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Gilead Sciences Right Now?Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a new agreement with the Pan American Health Organization (PAHO) to accelerate access to twice-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO Member States in Latin America and the Caribbean. Through PAHO's Regional Revolving Funds, the agreement establishes a coordinated regional pathway to expand access to long-acting HIV prevention and support country-led effor.
Logos of Gilead at the company’s booth at the 8th China International Import Expo (CIIE) in Shanghai, China, November 6, 2025.REUTERS/Maxim Shemetov Purchase Licensing Rights, opens new tab
CompaniesSept 15 (Reuters) - U.S. drugmaker Gilead Sciences (GILD.O), opens new tab said on Tuesday it had reached an agreement with the Pan American Health Organization to widen access to its HIV prevention drug across Latin America and the Caribbean, as the regions seek to curb new infections.
Under the new agreement, countries that choose to offer lenacapavir, a twice-yearly drug marketed as Yeztugo in the United States for HIV prevention, will be able to procure it through PAHO's regional purchasing system.
Sign up here.
New HIV infections in Latin America and the Caribbean rose 13% between 2010 and 2024, Gilead said, citing gaps in the utilization of HIV prevention medicines.
The agreement creates a new pathway to access in 14 countries that are not covered by its voluntary licensing agreements for generic versions, the company said.
Under a 2024 deal, it granted six generic manufacturers royalty-free licenses to produce and supply the drug in resource-limited countries.
Eligible countries include Argentina, Brazil, Chile, Colombia, Costa Rica, Ecuador, El Salvador, Guatemala, Mexico, Panama, Paraguay, Peru, Uruguay and Venezuela.
Yeztugo is a pre-exposure prophylaxis, or PrEP medicine, and is central to Gilead's growth strategy. The company has forecast $1 billion in sales for the long-acting drug in 2026.
PAHO Director Jarbas Barbosa said the initiative could help reduce access gaps to lenacapavir and give countries another option for HIV prevention.
Gilead is also in discussions with Brazil's Health Ministry on possible local production of lenacapavir, the company said.
It said its access plan includes generic licensing, technology transfers and partnerships. Availability will depend on country-specific decisions and regulatory approvals.
Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Pooja Desai
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Bank of America Corp DE lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 6.7% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,649,065 shares of the biopharmaceutical company’s stock after selling 1,329,871 shares during the quarter. Bank of America Corp DE owned approximately 1.50% of Gilead Sciences worth $2,356,123,000 at the end of the most recent reporting period.
Other hedge funds also recently modified their holdings of the company. BlackRock Inc. bought a new position in shares of Gilead Sciences during the 2nd quarter worth approximately $15,393,785,000. State Street Corp increased its position in shares of Gilead Sciences by 1.9% during the 4th quarter. State Street Corp now owns 60,240,518 shares of the biopharmaceutical company’s stock valued at $7,393,921,000 after purchasing an additional 1,151,213 shares during the last quarter. Norges Bank bought a new stake in shares of Gilead Sciences during the 4th quarter worth $2,617,152,000. Invesco Ltd. grew its position in Gilead Sciences by 2.9% during the fourth quarter. Invesco Ltd. now owns 15,584,341 shares of the biopharmaceutical company’s stock valued at $1,912,822,000 after buying an additional 444,660 shares during the period. Finally, Amundi increased its holdings in Gilead Sciences by 10.7% during the first quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock worth $1,468,836,000 after buying an additional 1,018,976 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.
Gilead Sciences Price Performance NASDAQ:GILD opened at $146.41 on Tuesday. Gilead Sciences, Inc. has a 52-week low of $108.46 and a 52-week high of $157.29. The stock has a fifty day moving average of $138.82 and a 200 day moving average of $136.18. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The firm has a market capitalization of $181.54 billion, a price-to-earnings ratio of -54.84 and a beta of 0.33.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping the consensus estimate of ($7.25) by $0.50. The company had revenue of $7.80 billion for the quarter, compared to analysts’ expectations of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. Gilead Sciences’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same period in the prior year, the business earned $2.01 earnings per share. On average, research analysts expect that Gilead Sciences, Inc. will post -0.48 EPS for the current fiscal year. Gilead Sciences Announces Dividend The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently -122.85%.
Insider Activity at Gilead Sciences In related news, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $145.02, for a total value of $725,100.00. Following the completion of the sale, the director owned 10,066 shares in the company, valued at $1,459,771.32. The trade was a 33.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of the stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $148.62, for a total transaction of $2,675,160.00. Following the transaction, the director owned 12,894 shares in the company, valued at $1,916,306.28. The trade was a 58.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 99,000 shares of company stock worth $13,747,860 in the last quarter. 0.30% of the stock is owned by company insiders.
Wall Street Analysts Forecast Growth A number of research analysts have weighed in on GILD shares. HSBC boosted their target price on shares of Gilead Sciences from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Royal Bank Of Canada increased their price target on Gilead Sciences from $120.00 to $123.00 and gave the stock a “sector perform” rating in a research note on Wednesday, August 5th. Morgan Stanley lowered their price objective on Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating on the stock in a research note on Monday, July 27th. Weiss Ratings downgraded shares of Gilead Sciences from a “buy (b-)” rating to a “hold (c-)” rating in a report on Tuesday, August 11th. Finally, Truist Financial cut their target price on shares of Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a research report on Tuesday, July 7th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average price target of $158.78.
View Our Latest Analysis on Gilead Sciences
Gilead Sciences Company Profile (Free Report)
Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company’s research focuses primarily on virology, oncology, inflammation and related areas, with products serving patients in the United States and international markets.
Gilead is best known for its HIV treatments, including Biktarvy, Genvoya, Descovy and other antiretroviral therapies. Its portfolio also includes medicines for viral hepatitis, such as Epclusa and Vemlidy, and Veklury (remdesivir), an antiviral treatment for COVID-19.
Further Reading Five stocks we like better than Gilead Sciences Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings Institutional Money Is Pouring Into These 2 Altcoin ETFs The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares 3 Dividend Kings to Buy While They’re Still Beaten Down
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
Gilead Sciences (NASDAQ:GILD – Get Free Report) and Grifols (NASDAQ:GRFS – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.
Insider and Institutional Ownership 83.7% of Gilead Sciences shares are owned by institutional investors. 0.3% of Gilead Sciences shares are owned by insiders. Comparatively, 0.2% of Grifols shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Recommendations This is a breakdown of current recommendations and price targets for Gilead Sciences and Grifols, as provided by MarketBeat.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gilead Sciences 0 5 23 1 2.86 Grifols 1 2 0 0 1.67 Gilead Sciences currently has a consensus price target of $158.78, suggesting a potential upside of 9.65%. Grifols has a consensus price target of $10.00, suggesting a potential upside of 30.72%. Given Grifols’ higher probable upside, analysts plainly believe Grifols is more favorable than Gilead Sciences. Dividends Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.3%. Grifols pays an annual dividend of $0.09 per share and has a dividend yield of 1.2%. Gilead Sciences pays out -122.8% of its earnings in the form of a dividend. Grifols pays out 47.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Gilead Sciences has raised its dividend for 10 consecutive years. Gilead Sciences is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
Volatility & Risk Gilead Sciences has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500. Comparatively, Grifols has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500.
Earnings and Valuation This table compares Gilead Sciences and Grifols”s gross revenue, earnings per share and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gilead Sciences $29.44 billion 6.10 $8.51 billion ($2.67) -54.24 Grifols $8.51 billion 0.61 $454.82 million $0.19 40.26 Gilead Sciences has higher revenue and earnings than Grifols. Gilead Sciences is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.
Profitability This table compares Gilead Sciences and Grifols’ net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets Gilead Sciences -10.64% -2.11% -0.75% Grifols 5.54% 6.21% 2.39% Summary Gilead Sciences beats Grifols on 11 of the 18 factors compared between the two stocks.
(Get Free Report)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
About Grifols (Get Free Report)
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
Baird Financial Group Inc. lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 3.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 292,295 shares of the biopharmaceutical company’s stock after buying an additional 10,206 shares during the quarter. Baird Financial Group Inc.’s holdings in Gilead Sciences were worth $36,929,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also modified their holdings of the stock. Aviva PLC increased its position in Gilead Sciences by 5.4% during the fourth quarter. Aviva PLC now owns 1,156,738 shares of the biopharmaceutical company’s stock worth $141,978,000 after purchasing an additional 59,782 shares during the last quarter. Life Cycle Investment Partners Ltd acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $1,418,000. Bank of Nova Scotia acquired a new position in Gilead Sciences in the second quarter valued at about $100,056,000. OMERS ADMINISTRATION Corp purchased a new position in shares of Gilead Sciences during the 2nd quarter worth approximately $55,754,000. Finally, Harvest Fund Management Co. Ltd boosted its position in shares of Gilead Sciences by 14.4% during the fourth quarter. Harvest Fund Management Co. Ltd now owns 106,526 shares of the biopharmaceutical company’s stock worth $13,075,000 after buying an additional 13,385 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.
Analyst Upgrades and Downgrades A number of research analysts recently weighed in on the stock. Truist Financial dropped their price objective on shares of Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a report on Tuesday, July 7th. Royal Bank Of Canada raised their target price on Gilead Sciences from $120.00 to $123.00 and gave the stock a “sector perform” rating in a research report on Wednesday, August 5th. HSBC boosted their price target on shares of Gilead Sciences from $155.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday. Weiss Ratings cut Gilead Sciences from a “buy (b-)” rating to a “hold (c-)” rating in a research note on Tuesday, August 11th. Finally, Daiwa Securities Group decreased their target price on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a research note on Tuesday, May 19th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $158.78.
Get Our Latest Stock Report on Gilead Sciences Insider Transactions at Gilead Sciences In other news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $137.64, for a total transaction of $3,853,920.00. Following the completion of the transaction, the insider owned 118,234 shares of the company’s stock, valued at $16,273,727.76. This represents a 19.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Dickinson sold 3,000 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $138.36, for a total transaction of $415,080.00. Following the transaction, the chief financial officer owned 165,646 shares in the company, valued at approximately $22,918,780.56. The trade was a 1.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 105,000 shares of company stock worth $14,495,820 in the last quarter. 0.30% of the stock is currently owned by corporate insiders.
Gilead Sciences Trading Down 0.6% Shares of GILD opened at $144.81 on Friday. The stock has a fifty day moving average of $138.24 and a two-hundred day moving average of $136.23. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The company has a market capitalization of $179.56 billion, a PE ratio of -54.24 and a beta of 0.33. Gilead Sciences, Inc. has a fifty-two week low of $108.46 and a fifty-two week high of $157.29.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($7.25) by $0.50. The business had revenue of $7.80 billion for the quarter, compared to analysts’ expectations of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The business’s revenue was up 10.6% on a year-over-year basis. During the same quarter last year, the firm earned $2.01 earnings per share. As a group, analysts forecast that Gilead Sciences, Inc. will post -0.48 EPS for the current year.
Gilead Sciences Dividend Announcement The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be given a dividend of $0.82 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 annualized dividend and a yield of 2.3%. Gilead Sciences’s dividend payout ratio is -122.85%.
Gilead Sciences Profile (Free Report)
Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company’s research focuses primarily on virology, oncology, inflammation and related areas, with products serving patients in the United States and international markets.
Gilead is best known for its HIV treatments, including Biktarvy, Genvoya, Descovy and other antiretroviral therapies. Its portfolio also includes medicines for viral hepatitis, such as Epclusa and Vemlidy, and Veklury (remdesivir), an antiviral treatment for COVID-19.
Recommended Stories Five stocks we like better than Gilead Sciences AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case Corning Just Locked In a Massive Verizon Fiber Deal as AI Infrastructure Expands 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
3 Blue-Chip Stocks Built for a Rotating MarketGilead Sciences NASDAQ: GILD CFO Andy Dickinson told attendees at the Cantor Global Healthcare Conference that the company sees continued growth opportunities across its HIV prevention and treatment businesses, while advancing programs in inflammation, oncology and cell therapy.
Dickinson said the launch of Sunlenca for HIV prevention is meeting or exceeding the company’s expectations across its metrics. Gilead has guided to roughly $1 billion in Sunlenca sales this year, he said, adding that the product had a 70% persistence rate as discussed at the end of the second quarter.
Get Gilead Sciences alerts:
These 3 Cash Flow Machines Provide Stability in Uncertain Markets“Every which way we look at it, the launch is going really well,” Dickinson said. “The prevention business overall is doing great, and we think it’s just the beginning of a long period of growth for that franchise.”
HIV Prevention Strategy Gilead’s HIV prevention business is currently operating at a $4 billion run rate, up from roughly $1.5 billion not long ago, according to Dickinson. He said the overall HIV prevention market has been growing at a mid-teens percentage rate, supported by greater awareness of prevention options, Sunlenca’s launch, growth in Descovy and pricing tailwinds.
3 Cash-Flow Machines Investors May Want Heading Into 2026The company expects long-acting prevention therapies to account for a growing share of the market over time. Gilead expects a yearly injectable version of lenacapavir, also known as Sunlenca, to be available in 2028. It also expects a weekly oral lenacapavir option to be approved in the U.S. next year.
Dickinson said the weekly oral could broaden access among people who do not want injectable treatment or who may prefer to move from daily oral medication to a weekly regimen. About 50% of the market currently uses generic daily oral Truvada, he said.
Gilead expects six-month and annual injectable options to coexist. While some physicians value seeing prevention patients twice annually, others and their patients may prefer a yearly intramuscular injection, Dickinson said.
BIKTARVY and HIV Treatment Pipeline BIKTARVY remains the company’s leading HIV treatment product, with roughly 52% share of U.S. patients receiving HIV treatment and more than 70% of new patient initiations, according to Dickinson. Although percentage growth has slowed as the product has grown larger, he said BIKTARVY can continue to expand.
Gilead recently received approval for Bexlenvo, a daily oral combination of bictegravir and lenacapavir. Dickinson said the product provides an opportunity for Gilead to participate more substantially in the HIV treatment switch market and could serve patients with significant resistance or other complications who are currently on multi-tablet regimens.
The company also expects to introduce a weekly oral treatment combination with Merck next year, followed over time by monthly oral and longer-acting injectable treatment regimens.
On BIKTARVY’s ongoing U.S. government drug-price negotiations under the Inflation Reduction Act, Dickinson said the company expects the impact beginning in 2028 to be manageable. He said the government is expected to publish the results at the end of November and that Gilead continues to expect its HIV treatment business to grow through 2030 and beyond. BIKTARVY has composition-of-matter patent protection through 2036, he noted.
Inflammation and Cell Therapy Programs Dickinson described inflammation and immunology as Gilead’s third core scientific area alongside virology and oncology. The company plans to present Phase II ulcerative colitis data for its alpha-4 beta-7 program at a scientific conference later this year and is advancing the program into Phase III as a monotherapy while exploring potential combinations.
Gilead has other internal inflammatory bowel disease assets, including a TYK2 inhibitor and gut-restricted FXR agonists, that could potentially support combination approaches. Dickinson said the company is also considering external partnerships, including for potential oral IL-23 combinations.
The company also expects data later this year or early next year from its B-cell depletion program through Ouro and partner Lakefront Bio, formerly Galapagos NV. Dickinson said the program is being evaluated in three relatively large orphan diseases.
In cell therapy, Gilead expects a decision later this year on anitocabtagene autoleucel and remains confident in its expectation for a fourth-line-plus label in multiple myeloma. Dickinson said the therapy could directionally double the size of Gilead’s cell therapy business and may later expand into second-line-plus treatment following a fully enrolled Phase III trial.
Portfolio and Capital Allocation Dickinson said Gilead’s recent acquisitions of Arcellx, Ouro and Tubulis add to a portfolio that has become more robust over the past decade. He highlighted Tubulis’ antibody-drug conjugate platform and its lead ovarian cancer program, for which data were presented at ASCO earlier this year.
Gilead expects to remain focused on oncology, virology and inflammation and immunology for the foreseeable future. Dickinson said the company will continue to pursue external innovation but has less need for major acquisitions than it did years ago because its internal research engine has expanded. Gilead now moves more than 10 molecules annually from research into clinical development, compared with roughly two to four annually when Dickinson joined the company 10 years ago.
He said the company expects to balance R&D investment, partnerships and operational efficiencies while prioritizing programs that could benefit patients.
About Gilead Sciences (NASDAQ:GILD)Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company's research focuses primarily on virology, oncology, inflammation and related areas, with products serving patients in the United States and international markets.
Gilead is best known for its HIV treatments, including Biktarvy, Genvoya, Descovy and other antiretroviral therapies. Its portfolio also includes medicines for viral hepatitis, such as Epclusa and Vemlidy, and Veklury (remdesivir), an antiviral treatment for COVID-19.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Gilead Sciences Right Now?Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Gilead Sciences, Inc. (GILD) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 11:00 AM EDT
Company Participants
Dietmar Berger - Chief Medical Officer
Conference Call Participants
Mohit Bansal - Wells Fargo Securities, LLC, Research Division
Presentation
Mohit Bansal
Wells Fargo Securities, LLC, Research Division
Awesome. Thank you very much for joining us today. My name is Mohit Bansal. I am one of the biotech and pharma analysts here at Wells Fargo, and I am joined by Dr. Dietmar Berger, Gilead's Chief Medical Officer. Thank you very much, Dietmar, for joining us today for the first time.
Dietmar Berger
Chief Medical Officer
Thanks for having me. Yes, of course.
Mohit Bansal
Wells Fargo Securities, LLC, Research Division
Awesome. Gilead has been a regular. This is fifth year in a row at Wells Fargo Conference, first time for Dietmar. We are excited to have some R&D discussions here.
Dietmar Berger
Chief Medical Officer
Yes.
Question-and-Answer Session
Mohit Bansal
Wells Fargo Securities, LLC, Research Division
So Dietmar, let's just talk a little bit about the pipeline focus right now. It does seem like you have a mix of, obviously, building on HIV, where you have a leadership, and then oncology, some datasets coming in, immunology as well. Talk a little bit about when you look at the internal portfolio and some of the assets you acquired earlier this year, where is the focus internally is, and then what do you see the most exciting stuff out there?
Dietmar Berger
Chief Medical Officer
Yes. No, thanks for that question. The current management team at Gilead, they joined 7 years ago. There was a clear realization that we want to diversify. That's been our strategy for some time, and we've clearly highlighted, yes, we have a clear stronghold in virology, and there's diversification in virology as well. That's important to us. Then there's really this expansion into oncology
Gilead Sciences NASDAQ: GILD Chief Medical Officer Dietmar Berger outlined the company's priorities across HIV, oncology and inflammation at the Wells Fargo conference, describing a portfolio that has expanded through internal development and acquisitions and is now entering a period of prioritization and execution.
California State Teachers Retirement System increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 12,498.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 241,168,657 shares of the biopharmaceutical company’s stock after acquiring an additional 239,254,365 shares during the quarter. California State Teachers Retirement System owned about 19.45% of Gilead Sciences worth $30,469,248,000 as of its most recent SEC filing.
A number of other large investors have also added to or reduced their stakes in the business. Persistent Asset Partners Ltd bought a new stake in shares of Gilead Sciences during the second quarter worth approximately $25,000. Strategic Investment Solutions Inc. IL acquired a new stake in Gilead Sciences during the 4th quarter worth approximately $25,000. Kimelman & Baird LLC bought a new stake in Gilead Sciences in the 2nd quarter valued at $25,000. Vermillion & White Wealth Management Group LLC grew its holdings in Gilead Sciences by 71.4% in the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 85 shares in the last quarter. Finally, Quattro Advisors LLC bought a new position in Gilead Sciences during the 4th quarter worth $26,000. Institutional investors own 83.67% of the company’s stock.
Wall Street Analyst Weigh In A number of brokerages have recently issued reports on GILD. Morgan Stanley reduced their target price on shares of Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating for the company in a research report on Monday, July 27th. HSBC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and boosted their price objective for the company from $133.00 to $155.00 in a report on Monday, July 6th. Daiwa Securities Group dropped their price target on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a research report on Tuesday, May 19th. Barclays reduced their price target on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 29th. Finally, Truist Financial dropped their price objective on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a report on Tuesday, July 7th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $158.04.
Read Our Latest Report on GILD Gilead Sciences Price Performance Shares of GILD stock opened at $150.99 on Tuesday. The business has a fifty day simple moving average of $137.17 and a 200 day simple moving average of $136.36. The company has a market cap of $187.22 billion, a P/E ratio of -56.55 and a beta of 0.33. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. Gilead Sciences, Inc. has a twelve month low of $108.46 and a twelve month high of $157.29.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. The firm had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.01 earnings per share. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post -0.48 EPS for the current fiscal year.
Gilead Sciences Announces Dividend The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be issued a dividend of $0.82 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.2%. Gilead Sciences’s dividend payout ratio is -122.85%.
Insider Buying and Selling In related news, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $137.64, for a total transaction of $3,853,920.00. Following the sale, the insider owned 118,234 shares of the company’s stock, valued at $16,273,727.76. This trade represents a 19.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of the business’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total value of $2,675,160.00. Following the sale, the director owned 12,894 shares in the company, valued at $1,916,306.28. This represents a 58.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 105,000 shares of company stock worth $14,495,820 in the last ninety days. Insiders own 0.30% of the company’s stock.
Gilead Sciences Company Profile (Free Report)
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
Recommended Stories Five stocks we like better than Gilead Sciences 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines Gilead Sciences, Inc. (Nasdaq: GILD) today celebrated the opening of its 182,000-square-foot Research Center at its Foster City headquarters, expanding capabilities in oncology, inflammation and research data science to advance medicines for some of the world’s most challenging diseases. The new Research Center builds on Gilead's longstanding presence in California. Today, Gilead employs approximately 11,000 people across the United States, including more than 7,400 in California and nearly 4,700 in the Bay Area.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908951870/en/
Gilead's new 182,000-square-foot Research Center in Foster City, Calif., marks the latest milestone in the company's $32 billion investment in U.S. research, development and manufacturing through 2030
Gilead marked the milestone with a ribbon-cutting ceremony attended by company leaders, scientists and government and community guests, including U.S. Representative Kevin Mullin of California’s 15th Congressional District and California State Assemblymember Diane Papan.
“We are in a moment of unprecedented opportunity in science and technology. Our new Research Center will help Gilead scientists make the most of that opportunity, delivering more breakthrough medicines faster," said Daniel O'Day, Chairman and Chief Executive Officer, Gilead Sciences. “As part of our broader $32 billion investment in the United States, this new facility also reflects our long-term commitment to American innovation."
The Research Center is one of three major Foster City projects advancing Gilead’s broader U.S. investment in research, development and manufacturing through 2030. The Technical Development Center, expected to open in 2027, and the biologics facility, which broke ground in August and is expected to open in 2029, will further strengthen Gilead’s U.S. research and development infrastructure. “The future of biomedical innovation depends on bringing together exceptional science, advanced technologies and diverse expertise,” said Flavius Martin, MD, Executive Vice President, Research, Gilead Sciences. “This center was designed to do exactly that. By co-locating key research disciplines and expanding our data science capabilities, we are strengthening the infrastructure needed to accelerate discovery and advance meaningful innovations.”
Designed with input from Gilead research colleagues, the five-story center will support approximately 325 employees, including 260 laboratory scientists. Flexible laboratory neighborhoods, specialized collaboration spaces and shared technology platforms will enable teams to adapt as scientific needs evolve. All-electric systems, energy-efficient design and water-saving landscaping featuring California native plants are expected to support LEED Gold certification.
“Foster City is home to some of the most important biomedical research happening anywhere in the world, and Gilead’s continued investment here is a vote of confidence in California’s life sciences workforce,” said Kevin Mullin, U.S. Representative for California’s 15th Congressional District. “The new center expands Gilead’s research capacity in Foster City, supporting the region’s biotechnology leadership and skilled workforce.”
A dedicated bridge to an adjacent building streamlines the transfer of equipment and research materials, while the new Research Quad provides a central gathering space for collaboration and scientific exchange.
“San Mateo County is one of the most important and vital biotechnology centers in the world,” said Diane Papan, California State Assemblymember, 21st District. “Gilead’s sustained support for science, infrastructure and skilled jobs only strengthens our position.”
For more information about Gilead's U.S. investments, visit Gilead's U.S. investment webpage.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. In 2025, Gilead announced a $32 billion investment to further strengthen its U.S. footprint to power the next era of discovery, job creation and public health preparedness – while continuing to invest globally to ensure patients everywhere benefit from its scientific innovation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead’s ability to effectively manage or realize the anticipated benefits from its U.S. investment strategy, including the new Research Center, the Technical Development Center or the biologics facility; difficulties or unanticipated challenges in executing the investment strategy, including Gilead’s ability to complete planned initiatives in a timely basis or at all and uncertainties relating to regulatory approvals that may be required; any resulting adverse impacts to our corporate reputation; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and factors are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements.
For more information about Gilead, please visit the company's website at www.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).
View source version on businesswire.com: https://www.businesswire.com/news/home/20260908951870/en/
Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.
In the latest trading session, Gilead Sciences (GILD - Free Report) closed at $146.64, marking a -2.88% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.58%. Meanwhile, the Dow experienced a drop of 1.18%, and the technology-dominated Nasdaq saw a decrease of 0.32%.
Shares of the HIV and hepatitis C drugmaker have appreciated by 13.48% over the course of the past month, outperforming the Medical sector's gain of 2.73%, and the S&P 500's loss of 0.36%.
The investment community will be paying close attention to the earnings performance of Gilead Sciences in its upcoming release. On that day, Gilead Sciences is projected to report earnings of $2.15 per share, which would represent a year-over-year decline of 12.96%. Simultaneously, our latest consensus estimate expects the revenue to be $7.79 billion, showing a 0.3% escalation compared to the year-ago quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$0.48 per share and a revenue of $30.74 billion, signifying shifts of -105.89% and +4.39%, respectively, from the last year.
Investors should also take note of any recent adjustments to analyst estimates for Gilead Sciences. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 6.01% higher. Gilead Sciences is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 162, positioning it in the bottom 35% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
Compass Financial Management LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 5,244 shares of the biopharmaceutical company’s stock, valued at approximately $671,000.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in Gilead Sciences during the 2nd quarter valued at about $15,393,785,000. Norges Bank acquired a new position in shares of Gilead Sciences during the 4th quarter worth approximately $2,617,152,000. Legal & General Group Plc purchased a new stake in shares of Gilead Sciences in the second quarter valued at approximately $1,316,606,000. Deutsche Bank AG acquired a new stake in shares of Gilead Sciences in the second quarter valued at approximately $918,387,000. Finally, Boston Partners acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $517,808,000. Institutional investors and hedge funds own 83.67% of the company’s stock.
Gilead Sciences Trading Down 0.0% NASDAQ GILD opened at $150.99 on Monday. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The stock has a market capitalization of $187.22 billion, a P/E ratio of -56.55 and a beta of 0.33. The firm’s 50-day moving average is $136.67 and its two-hundred day moving average is $136.39. Gilead Sciences, Inc. has a 12 month low of $108.46 and a 12 month high of $157.29.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. The business had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same period last year, the business earned $2.01 earnings per share. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post -0.48 earnings per share for the current year. Gilead Sciences Dividend Announcement The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be given a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. Gilead Sciences’s dividend payout ratio (DPR) is presently -122.85%.
Wall Street Analyst Weigh In A number of equities analysts have weighed in on the company. HSBC raised Gilead Sciences from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $133.00 to $155.00 in a research note on Monday, July 6th. Maxim Group raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price for the company in a research note on Wednesday, May 20th. Truist Financial reduced their price target on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a report on Tuesday, July 7th. Needham & Company LLC reissued a “buy” rating and set a $170.00 price target on shares of Gilead Sciences in a research report on Wednesday, August 5th. Finally, Rothschild & Co Redburn dropped their price objective on shares of Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $158.04.
Get Our Latest Analysis on Gilead Sciences
Key Stories Impacting Gilead Sciences Here are the key news stories impacting Gilead Sciences this week:
Positive Sentiment: New HIV and oncology approvals broaden Gilead’s growth prospects. FDA approval of Bixlenvo, a once-daily single-tablet HIV regimen for virologically suppressed adults on complex treatments, could strengthen the company’s HIV franchise. Separately, European approval of Trodelvy plus Keytruda for certain first-line metastatic triple-negative breast cancer patients expands Gilead’s oncology opportunity. Commercial uptake will determine the ultimate revenue impact. HIV and oncology approvals article Positive Sentiment: Analysts raised long-term earnings expectations. Zacks Research increased its Q1 2028 EPS estimate to $2.15, Q2 2028 to $2.31 and FY2028 to $9.66, while maintaining a “Strong Buy” rating. The revisions suggest improving confidence in Gilead’s future profitability. Gilead analyst estimates Positive Sentiment: An Arcus-backed cancer study reached completion. The milestone sets up a potentially important immuno-oncology catalyst, although investors will likely need to wait for efficacy and safety data before assigning significant value to the program. Arcus-backed cancer trial article Neutral Sentiment: Gilead continues to support income investors with a $0.82 quarterly dividend. The $3.28 annualized payout provides shareholder support, but the high payout relative to reported earnings makes future dividend growth dependent on sustained HIV cash flow and successful new-product launches. Gilead dividend article Neutral Sentiment: CEO Daniel O’Day sold $2.23 million of stock. The 15,000-share sale reduced his holdings by 2.53%, but it was completed under a pre-arranged Rule 10b5-1 plan, limiting its value as a bearish signal. SEC insider trading filing Negative Sentiment: Investors remain concerned about concentration and patent-expiration risk. Gilead’s dividend and cash generation depend heavily on its leading HIV franchise, particularly a blockbuster therapy facing a known patent expiration later in the next decade. The sharp decline in cell-therapy licensing deals also highlights uncertainty around diversification beyond HIV. Gilead dividend and patent risk article Insider Transactions at Gilead Sciences In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $137.64, for a total transaction of $3,853,920.00. Following the transaction, the insider directly owned 118,234 shares in the company, valued at $16,273,727.76. This represents a 19.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O’Day sold 15,000 shares of Gilead Sciences stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $148.64, for a total value of $2,229,600.00. Following the completion of the sale, the chief executive officer directly owned 577,133 shares of the company’s stock, valued at $85,785,049.12. The trade was a 2.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 105,000 shares of company stock worth $14,495,820 in the last three months. Company insiders own 0.30% of the company’s stock.
Gilead Sciences Company Profile (Free Report)
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
Further Reading Five stocks we like better than Gilead Sciences AI Token Costs Are Changing the Hardware vs. Software Debate 3 ETFs That Could Move as Rate Expectations Shift 3 Stocks With September Catalysts Investors Shouldn’t Ignore Ollie’s Bargain Outlet Stock Falls on Weak Comps Despite Margin Gains
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
